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Abstract

STEM CELL FACTOR AND KIT EXPRESSION IN TYPE I NEUROFIBROMATOSIS
By Kenneth Eugene Roth, B . S .
A dissertation submitted i n partial fulfillment o f the requirements for the degree o f Doctor o f
Philosophy a t Virginia Commonwealth University
Virginia Commonwealth University, 1 997
Director: Thomas F. Huff, Ph.D., Professor, Department of Microbiology and Immunology

Neurofibromatosis type I (NF 1) is an inherited disease characterized by the appearance
of multiple neurofibromas and an increased incidence of malignant schwannomas, both of
which contain hyperproliferative Schwann cells. Our laboratory previously reported that
Schwann cells produce stem cell factor (S CF), a multi potential growth factor known to b e
involved i n mast cell migration and growth. Given t h e fact that mast cell numbers are
increased in both neurofibromas and malignant schwannomas, we set out to evaluate a
potentia! role for SCF in the development of NFl lesions. First we studied the effects of high
doses of recombinant SCF on mast cell numbers in vivo, and found that dermal and peritoneal
mast cell numbers were decreased. Next, we examined the expression of stem cell factor and
its receptor, Kit, in neurofibromas and malignant schwannoma tumors and cell lines.
Using an RNase protection assay, we find that each of four human malignant
schwannoma cell lines express only the membrane-bound isoform of S CF messenger RNA.

Xlii

In contrast, neurofibroma, vestibular schwannoma, and acoustic neuroma tissues, as well as
the majority of human fibroblast sources, all express the soluble form. Low level expression
of Kit protein was detected on all four malignant schwannoma cell lines. However, Kit
expression by S chwann cells was not indicated by immunohistochemical analyses of
neurofibroma and malignant schwannoma sections, although Kit was readily detected on the
mast cells within these lesions. We report that bone marrow-derived mouse mast cells appear
t o b e driven toward a connective tissue phenotype when cultured in the presence of
conditioned media from Schwann cells of wild type and NFl +/- knockout mice. This effect
was not observed in cultures containing conditioned medium from Schwann cells of NFl -/
knockouts . In addition, the latter appeared to augment the proliferation of mast cells in
response to exogenous cytokines.
Together, these results suggest a significant role for stem cell factor and Kit in the
lesions of NFl. In addition, functional neurofib romin, the product of the NFl gene, may be
required for proper regulation of SCF isoform expression. The mechanisms by which this
expression is regulated remain to be clearly defi n ed.

Introduction

Type 1 neurofibromatosis (NF l ) is among the most common inherited human diseases,
affecting one out of 3 500 individuals worldwide (Stumpf et aI. , 1 987). The responsible gene
has been cloned and is located on the long arm of chromosome 17 (Barker et aI . , 1 987). The

NFl eDNA reveals that the gene encodes a large protein, called neurofibromin, which
contains a region with homology to mammalian Ras GTPase-activating protein (GAP) and
the yeast GAP-like proteins IRA I and lRA2 (Xu et aI . , 1 990). Each of these proteins has
been shown to inactivate Ras p2 1 , the product of the

ras

protooncogene (Tanaka et aI . ,

1 990). Ras p2 1 is activated when i t i s bound t o guanosine triphosphate (GTP), and becomes
i nactive when GTP is converted to guanosine diphosphate (GDP) by its intrinsic GTPase
activity. GAP and GAP-related proteins induce this activity, thereby serving as negative
regulators ofRas. It has been reported that the GAP-related domain of neurofi b romin indeed
has GAP-like activity against Ras p2 1 , supporting the postulation that neurofibromin
functions as a tumor suppressor (Weinberg, 1 99 1 ).
The clinical manifestations ofNF I are generally associated with the peripheral nervous
system. Two phenomena which occur at an increased rate of incidence in NF I patients
involve hyperproliferation of Schwann cells, which are intimately associated with peripheral
nerves and are normally responsible for the formation of the myelin sheath around them.
These conditions are termed neurofibromas and malignant schwannomas. The appearance of

2
neurofibromas is a hallmark characteristic of the disease. These are benign peripheral nerve
tumors consisting primarily of Schwann cells, which account for 60-85% of the cellular
composition. Fibroblasts make up an additional 1 0-20%, with pericytes, perineurial cells,
mast cells, endothelial cells and smooth muscle cells also present (Peltonen et aI . , 1 988). It
has long been known that neurofibroma tissues contain increased numbers of mast cells
(Isaacson, 1 976; Johnson et aI. , 1 989), but the mechanism by which this occurs has not been
well understood. Mast cells can normally be found in perineurial and epineurial spaces of
peripheral nerves (Bienenstock et aI., 1 99 1 ), and are often seen in close proximity to Schwann
cells (Isaacson, 1 976). In addition, dramatic increases in mast cell numbers are observed in
situations involving peripheral nerve injury and repair (Isaacson, 1 976) . Neither the means
by which this occurs, nor a potential role for mast cells in these processes has yet been clearly
defined.
The second NF l -related condition involving altered Schwann cell growth is the
malignant schwannoma, which is also known by other names, including neurofib rosarcoma
and malignant peripheral nerve sheath tumor.

These occur much less frequently than

neurofibromas, with an incidence of up to 2% in NF l patients (Ponder, 1 990; Nimura, 1 992).
This is, however, a significantly higher rate of occurrence than that seen in genetically normal
individuals «< 1 % (Cutler and Gross, 1 93 6)). Given the known involvement of Ras p 2 1 in

the regulation of cellular proliferation, and the evidence that neurofibromin is able to
functionally regulate the activity of Ras p2 1 , it seems plausible that the NF I gene defect alone
could be responsible for these Schwann cell disorders. This, however, does not appear to be
the case.

All patients with NF l appear to have mutations within the same region of
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chromosome 1 7 (Barker et aI. , 1 987; Collins et aI. , 1 988; S eizinger et aI . , 1 987), but not all
have neurofibromas (ponder, 1 990; Riccardi, 1 982) and even fewer develop malignant
schwannomas, suggesting that additional mutations or other influences are required (Ratner
et aI. , 1 990).
Our laboratory described a soluble factor produced by normal but not Sleel (Sf)
murine fibroblasts which could promote the growth of mast cells in vitro (Jarboe et aI . , 1 989).
Since then the Sf product, now known as stem cell factor (S CF), has been more fully
characterized in both rodent and human, and is known to exist as either a soluble or
membrane-bound protein, dependent upon whether the portion of the primary gene transcript
encoded by exon 6 is included in the final messenger RNA (Flanagan et aI . , 1 99 1 ) . The exon
6-containing mRN A gives rise to a protein that contains a protease-sensitive site in an
extracellular membrane-proximal location. This isoform of SCF, after being initially expressed
as a membrane-inserted protein, is efficiently cleaved by an unidentified protease, releasing
a biologically active growth factor. S oluble SCF has been described as a potent chemotactic
agent for cells that express its receptor Kit, the product of the protooncogene c-kil (Blume
Jensen et aI., 1 9 9 1 ; Meininger et aI ., 1 992)' We recently reported that normal rodent and
human Schwann cells, and the human malignant schwannoma cell line ST88- l 4, all produce
SCF (Ryan et al., 1 994). Interestingly, Hirota and colleagues noted higher levels of stem cell

factor mRNA in neurofibroma tissue compared with normal skin and suggested that SCF may
be involved in the increased numbers of mast cells in these lesions (Hirota et aI . , 1 993 ) S ince
mast cells express the Kit receptor, one might speculate that the mast cells in a neurofibroma
m ay be recruited to the site by the chemotactic activity of soluble SCF. We have also
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reported that, although normal rodent and human S chwann cells do not express Kit, the
ST8 8 - 1 4 malignant schwannoma line aberrantly expresses Kit mRNA and protein (Ryan et
aI. , 1 994). These findings have led us to consider whether the abundant growth of S chwann
cel l s found in neurofibromas and malignant schwannoma tumors might be due to the
simultaneous expression of SCF and its receptor by S chwann cells, resulting in an autocrine
growth loop. In this study, we evaluate Kit expression in three additional human malignant
schwannoma cell lines and in excised neurofibroma and schwannoma tumors. In addition, we
determine which isoform of SCF mRNA is produced by these and other sources.

Literature Review

Neurofibromatosis type I (NFl) and neurofibromin

The first full characterization of NF I is generally credited to Friedrich von
Recklinghausen, who described the disease in 1 882 (von Recklinghausen, 1 8 82). It is for this
reason that NFl has become known as von Recklinghausen neurofibromatosis, or more
simply, von Recklinghausen ' s disease. There were, however, some less detailed medical
descriptions recorded prior to von Recklinghausen ' s account. Two independent reports had
previously described the disease in multiple family members (Virchow, 1 8 57 ; Hitchcock,
1 862), while the first known descriptions date back to the eighteenth century (Akenside,
1 785; Tilesius, 1 793 ). It was not until early in the twentieth century that neurofibromatosis
was determined to be a genetic disorder (Thomson, 1 900; Adrian, 1 90 I; Prieser and
D avenport, 1 9 1 8) . With a worldwide rate of incidence of about I in 3 5 00 (Stumpf et aI . ,
1 987), NFl i s actually quite a common disease, yet i t has generally received very little public
attention.

Perhaps the most significant influence promoting public awareness of

neurofibromatosis has been the incorrect assumption that Joseph Merrick, a grotesquely
d isfigured man of Victorian England whose life was chronicled in the literary work, The
Elephant Man (Treves, 1 923), suffered ITom NF I and some of its most serious complications

(Montague, 1 97 1 ; Sparks, 1 980). However, after extensive examination of Merrick's remains
and medical records, it has been suggested that he actually did not have NF I, but likely
5

6
suffered from a disease known as the Proteus syndrome (Cohen, 1 988).

Nonetheless,

Merrick ' s life and social struggles have been portrayed in theater, cinema and television,
bringing widespread attention to neurofibromatosis, albeit through an error in diagnosis. Even
today some still refer to NFl as, "the Elephant Man ' s disease." Interestingly, it has also been
suggested that Quasimodo, the hunchback in Notre Dame de Paris, was created by playwright
Victor Hugo based upon his acquaintance with someone who had NF I (Hecht, 1 989;
S olomon, 1 968).
Neurofibromatosis type 1 is caused by a mutation in a gene (NFl) which has been
mapped to the long arm of human chromosome 17 (Barker et aI . , 1 987), and has since been
cloned (Cawthon et aI . , 1 990; Viskochil et aI . , 1 990; Wallace et aI . , 1990). It is inherited in
an autosomal dominant fashion with a penetrance of the mutated gene considered to be very

nearly 1 00 percent (Riccardi, 1 992). The disease is characterized by the formation of multiple
cutaneous and subcutaneous neurofibromas, which are benign tumors of the nerve sheath.
Although these lesions are rarely fatal, they are disfiguring and can be quite painful. There
i s remarkable variability in the number, location and size of the tumors, all of which can
contribute to the degree of disfigurement and pain. Additional symptoms of NF I include
l ocalized hyperpigmentation of skin, termed cafe-au-Iait spots, axillary freckling, iris
hamartomas (Lisch nodules), and sometimes more serious tumors, such as optic gliomas and

neurofibromas of spinal nerve roots. NF I patients appear to have an increased incidence of
certain cancers (Riccardi, 1 992; Huson and Hughes, 1 994), particularly malignant
schwannomas (neurofibrosarcomas), which are generally fatal (Bernards et aI . , 1 992) . The
gene is very large, spanning approximately 3 5 0 kilobases (kb) of genomic DNA, encoding an

7
mRNA of 1 1 to 1 3 kb, and containing at least 56 exons (Heim et a!. , 1 994). S equence
analysis reveals an open reading frame of28 1 8 amino acids, although alternative splicing may
encode different protein isoforms (Marchuk et a!. , 1 99 1 ) .

This large protein, called

neurofibromin, contains a region of 3 6 0 amino acids which shows significant similarity to the
catalytic domains of mammalian GTPase activating protein (GAP), as well as to the IRA] and
IRA2 gene products in yeast, which are inhibitors of the

ras

proto oncogene product (Xu et

aI., 1 990). Interestingly, during the course of efforts to characterize the NFl gene, three
active genes were found embedded within an intron. These genes, OMGP, EVI2B, and
EVI2A, are transcribed in the opposite orientation from the NFl gene, and encode

oligodendrocyte-myelin glycoprotein and ecotropic viral integration sites 2B and 2A,
respectively (Viskochil et a!. , 1 9 9 1 ) .
Ras p2 1 (hereafter referred t o simply a s Ras) i s the product o f the ra s protooncogene,
and can act as a source for either mitogenic or differentiation-inducing signals, depending on
the cell type (Bar-Sagi and Feramisco, 1 9 8 5 ; Hagg et a!. , 1 986; Noda et a!. , 1 985). The
protein i s physiologically quiescent when bound to guanosine diphosphate (GDP), and
becomes activated when the GDP is replaced with guanosine triphosphate (GTP). It returns
to the inactive state when the GTP is hydrolyzed to GOP by a GTPase activity intrinsic to
Ras. GAP and other GAP-like proteins inhibit Ras function by stimulating this hydroly si s.

The GAP-related domain (GRO) of neurofibromin has been shown to bind R as proteins avidly
and to stimulate their GTPase activities (Martin et a!. , 1 990c), suggesting that neurofibromin
functions as a tumor suppressor (Weinberg, 1 99 1 ) .
Perhaps due in part to its extensive size, the NFl gene seems to have a predisposition
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to mutate, with 5 0% of NFl cases thought to be due to new mutations. Although the GRD
of neurofibromin has been studied rather extensively, computer searches have revealed little
similarity between the remainder of sequence and any known proteins in current databases.
Therefore, the full function ofneurofibromin, and any pathological changes which may occur
as a consequence of a mutation at the NFl locus, are not yet well defined. There is evidence
that the function of neurofibromin is not limited to its ability to regulate Ras activity. Johnson
and coworkers showed by a series of transfection studies that neurofib romin, when
overexpressed in NIH 3 T3 cells, can inhibit cell growth independently of its GAP-like activity.
They also found that melanoma and neuroblastoma cell lines which lack neurofibromin do not
have increased levels of active Ras (Johnson et aI . , 1 994) . These findings are consistent with
later work done by Griesser, et al. which showed that melanocytes cultured from NF I patients
(from both cafe-au-lait spots and normally pigmented skin) had reduced levels of
neurofibromin, but still showed similar amounts of GTP-bound Ras when compared to
melanocytes from healthy donors (Griesser et aI . , 1 995). In a study conducted to determine
if neurofibromin is involved in melanogenesis, it was found that coexpression of
neurofibromin in a melanoma cell line caused an increase in expression of a reporter gene
under the control of the tyrosinase gene promoter (Suzuki et aI . , 1 994) . Tyrosinase is a rate
limiting enzyme in melanin biosynthesis and is expressed only in melanin-producing cells.

These investigators further showed that the GRD of neurofibromin was mainly responsible
for this induction (Suzuki et aI . , 1 994)
Two alternatively spliced isoforms of NFl messenger RNA have been identified and
tenned type 1 and type 2 (Anderson et aI . , 1 993; Nishi et aI . , 1 99 1 ). The two differ by a 63
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base pair insertion in the GAP-related domain of the type 2 isoform. Bernards and coworkers
showed by S I nuclease protection experiments that the two NFl mRNAs are widely
expressed in human cell lines and tissues, but that the ratio of the two forms differed
substantially between cell lines (Bernards et a!. , 1 992). Gutmann and colleagues have
reported that type I appears to be associated with cellular proliferation, and that the isoform
expression switches to predominantly type 2 when the cells undergo differentiation (Gutmann
et aI. , 1 993).
Until recently, NF I research has been somewhat hampered by the lack of a good
animal model system. In the 1 980s a naturally occuring disease in the bicolor damselfish
(Pomacentrus partitus), termed damselfish neurofi b romatosis (DNF), was introduced as a

possible model for human NFl (Schmale et aI . , 1 98 3 ; Schmale et aI . , 1 986)

These fi sh

exhibit multiple neurofibromas and malignant schwannomas, many of which are
hyperpigmented, indicating similarities to some of the manifestations of human NF I .
However, while NFl i n humans is inherited a s a n autosomal dominant mutation, DNF is a
transmissible disease (Schmale and Hensley, 1 988).

Nakamura and coworkers induced

multiple neurofibromas, melanomas, Wilms' tumors, and pheochromocytomas in Syrian
golden hamsters by transplacental administration of N-Nitroso-N-ethylurea (ENU) and
considered this as an animal model for human NF I (Nakamura et a!. , 1 989). Perhaps the most

promising model to date is a strain of mouse recently developed which contains a targeted
mutation in the NFl gene (Jacks et aI . , 1 994). Although animals which are heterozygous for
this mutation (homozygotes die in utero) do not exhibit the classical symptoms of human

NFl, they do have a high disposition to develop pheochromocytomas and myeloid leukemia,
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both of which occur with increased frequency in human NF l patients. Surely these models
will allow for a better understanding of NF l and the symptoms associated with the disease.

Schwann cells

Axons in the nervous system are supported, protected, and in some cases myelinated
by various cell types collectively known as glial cells (from the Greek word for "glue"). In
the peripheral nervous system (PNS) the glial cell providing these functions is the Schwann
cell. S chwann cells are derived from the neural crest cells which form during neural tube
development in embryogenesis (Dupin et aI . , 1 990; Zimmer and Le Douarin, 1 993). As the
embryo develops, neural crest cells migrate and eventually differentiate into highly specialized
cell types of neuronal, glial, melanocytic and mesectodermal phenotypes (Le Douarin and
Dupin, 1 993). Fully differentiated neural crest derivatives include Schwann cells, ganglion
satellite cells, most of the neurons of the PNS, melanocytes, and part of the cranial
mesenchyme (Dupin et aI . , 1 990). During early nervous system development, Schwann cell
precursors migrate with the developing axons and mUltiply rapidly to accommodate axonal
growth (Asbury, 1 967; Lemke, 1 990) . Jessen and Mirsky have characterized Schwann cell
development in the embryonic rat peripheral nervous system according to changes in antigenic
properties (Jessen and Mirsky, 199 1) . They report that Schwann cell precursors, identifiable

by embryonic day 1 5 , give rise to two morphologically and antigenically distinct mature
S chwann cell types. These are the myelin-forming cells associated with axons of larger
diameter, and the non-myelin-forming cells which associate with smaller axons.
S chwann cell development is dependent upon a close association between Schwann

11
cells and axons. In vivo studies have demonstrated that neurites supply Schwann cells with
mitogenic signals (Asbury, 1 967; Aguayo et ai , 1 976; Raine, 1 977). These findings were
supported by in vitro studies which showed that contact with the neuronal surface caused
S chwann cells to replicate (Salzer and Bunge, 1 980; Ratner et ai , 1 987). The activities
responsible for this stimulation have been localized to the neuronal cell surface (Salzer and
Bunge, 1 980; Ratner et ai, 1 98 8; Mason et ai, 1 989; Wood and Bunge, 1 975; Salzer et ai ,
1 980; S obue et ai , 1 983), but no specific mitogenic proteins had been identified until the
recent characterization of a family of proteins arising from alternative splicing of a single gene.
These proteins include glial growth factor (GGF, Marchionni et ai. , 1 993), heregulins (HRG,
Holmes et ai , 1 992), neu differentiation factor (NDF, Wen et ai , 1 992), and acetylcholine
receptor inducing activity (ARlA, Falls et ai , 1 993). GGF has been shown to be a potent
mitogen for rat Schwann cells (Lemke and Brockes, 1 984). Morrissey and others have
determined that heregulin is involved in the axon-induced mitogenesis of human S chwann
cells and that the receptor tyrosine kinase p I 85"b02 appears to be the cognate protein on the
S chwann cell (Morrissey et ai , 1 995; Levi et ai , 1 995).
The mitogenic effect ofaxons can be mimicked in vitro by agents which elevate cyclic
adenosine monophosphate (cAMP), suggesting that axon-associated signals mediate their
effects by elevating cAMP. In flllther in vitro studies it was found that the cAMP-induced
progression from a premyelination state to a myelination state required that the cell s withdraw
from the cell cycle. This raises the possibility that, in order for a mature S chwann cell to
begin myelination in vivo, it may require signals which suppress proliferation (Jessen and
Mirsky, 1 99 1 ) . Direct cell-cell contact is not an absolute requirement for neurons to regulate
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all S c hwann cell gene expression, however. Using an in vitro co-culture system in which
primary neurons and adult Schwann cells are separated by a microporous membrane,
investigators showed that diffusible molecules produced by neurons can repress expression
of the nerve growth factor receptor p75NGFR in Schwann cells, while inducing expression of
the myelin protein Po (Bolin and Shooter, 1 993).
Under normal circumstances in the fully developed organism, the S chwann cell no
longer undergoes cell division (Peters and Muir, 1 959; Asbury, 1967) . The intimate axon
S chwann cell association is retained, and the Schwann cell remains essentially quiescent
throughout the life of the animal (Asbury, 1 967) unless disrupted by injury or disease,
resulting in alteration of the normal metabolism of either of the cell types. Under pathological
conditions such as peripheral nerve injury, demyelination, and tumorigenesis, the Schwann cell
can be reactivated to enter the cell cycle (DeVries, 1 993). The signals required for this
reactivation are not yet known, although changes in Schwann cell gene expression resulting
from loss of axonal contact have been described. While neonatal rat Schwann cells grown
alone in culture express membrane-bound stem cell factor (SCF), those grown in contact with
dorsal root ganglion (DRG) neurites do not (Ryan et aI., 1 994). This raises the possibility that
loss of axonal contact induces expression of SCF by Schwann cells. Expression of other
proteins is induced following loss of axonal contact as a result of nerve damage. These
include vimentin, neural cell adhesion molecule (N-CAM), glial maturation factor p , and nerve
growth factor receptor IT (NGF-R II). Expression of each of these proteins decreases with
subsequent nerve regeneration (Jessen et aI . , 1 987a; Lemke and Chao, 1 988; Taniuchi et aI.,
1 98 8 ; Bosch et aI . , 1 989; Neuberger and Cornbrooks, 1 989; Mitchell et aI . , 1 990). In
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contrast, loss of axonal contact due to nerve damage causes a decrease in expression of
myelin-associated glycoprotein, the myelin basic proteins, the S chwann cell myelin-associated
proteins P2 and Po, and galactocerebroside. Expression of these proteins returns to normal
levels following nerve regeneration (Jessen et aI, 1 987b; Lemke and Chao, 1 98 8 ; Gupta et
aI. , 1 990; LeBlanc and Poduslo, 1990; Mitchell et aI, 1 990).
These examples of Schwann cell gene regulation by axons are likely involved in the
process by which damaged nerves are repaired .

A number of studies suggest that the

presence of Schwann cells is very impOJ1ant in nerve repair. Following crush injury to the
optic nerves of rats, regions containing resident Schwann cells were regenerated, whereas no
regeneration occurred in those areas in which Schwann cells were absent (Berry et aI, I 992a) .
In addition, when sections of optic nerve were engrafted between the stumps of freshly
transected sciatic nerves, regeneration only occurred through grafts containing S chwann cells
(Hall et al. , 1 992). One possible explanation for this preferential regrowth is that the S chwann
cells may be able to overcome the inhibitory effects of putative reactive elements within the
glial microenvironment. Oligodendrocytes and central nervous system (CNS) myelin have
been implicated in the failure of CNS axons to regenerate after injury (BerlY, 1982; S chwab
and Thoenen, 1 985; Caroni and Schwab, 1988), perhaps because of molecules associated with
both elements which inhibit axonal regrowth (Schwab and Caroni, 1 988). It is also suggested
that Schwann cells contribute to axonal regeneration because they secrete trophic molecules
(Varon and Williams, 1986), and sequester growing axons within basal lamina tubes (Berry
et al., 1 988; Hall and Berry, 1 989), possibly isolating growth cones from inhibitory influences
(Berry et aI , 1 99 1 , 1 992b).
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Mitogenic activity can be extracted from neurofibromas (Ratner et aI . , 1 990), but it
i s not clear whether this is important in tumor formation, or whether similar mitogens are
present in normal peripheral nerves. However, Schwann cells, but not fibroblasts, isolated
fro m NFl tumors show angiogenic and invasive properties in the chick chorioallantoic
membrane (Sheela et aI., 1 990) . These effects were not seen when cells from normal human
peripheral nerves were used, suggesting that neurofibroma Schwann cells secrete one or more
growth factors that normal Schwann cells do not It is unclear whether Schwann cells isolated
from normal regions of peripheral nerves ofNF I patients display these abnormal angiogenic
and invasive characteristics. This information would be helpful in determining why tumors
occur only in limited locations and only in some patients, even though the mutation is
ubiquitously expressed (Xu et aI . , 1 990; Wallace et aI . , 1 990). Either the NFl mutation
causes all Schwann cells to secrete angiogenic activity, or additional mutations or other
epigenetic changes lead to secretion of this activity only by the tumor cells (Eccleston, 1 992).
The latter possibilities would explain why neurofibromas are restricted to discrete areas.

Mast cells in neurofibromas

Mast cell numbers increase in response to nerve damage and repair. This phenomenon
has been observed in amputation neuromas (Olsson, 1 97 1 ), peripheral nerve injury and
pathological conditions involving Schwann cells, such as the lesions ofNF I (Isaacson, 1 976).
A greater degree of mast cell hyperplasia is seen in NFl tumors than in other forms of nerve
damage (Johnson et aI . , 1 989). The involvement of mast cells in these lesions continues to
be a focus of investigation in this laboratory. We have suggested (Roth et aI . , submitted for
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publication) that mast cells or their precursors are perhaps recruited to the site by the
chemotactic activity of soluble stem cell factor (possibly produced by Schwann cells) .
Alternatively, they may be trapped there by the binding of Kit on their surfaces to membrane
associated SCF expressed by the already hyperplastic Schwann cells in the growing lesion.
Although a clearer understanding of the means by which mast cells accumulate at the site of
a neurofibroma is important, perhaps more so is the potential contribution of mast cells to the
pathogenesis of the tumor itself, or of NF l in general . Riccardi has hypothesized that mast
cells accumulate following local trauma (or the elaboration or sequestering of a tropic factor)
and secrete various substances as usual . Due to an NFl mutation, the response is abnormal,
resulting in a proliferation of Schwann cells, fibroblasts, perineurial cells, etc., the
manifestation of which is a growing neurofibroma (Riccardi, 1 990).

Although this is

speculation at this point, it is not without merit. Mast cells secrete a variety of substances
with potential mitogenic effects, including heparin and histamine, as well as the well known
mitogen transforming growth factor-p (Pennington et aI ., 199 1). Giorno and others have
demonstrated by transmission electron microscopy that neurofibromas contain, in addition to
fully granulated mast cells, both partially and fully degranulated cells, indicative of activation
and mediator release (Giorno et aI ., 1989). These findings suggest that mast cells are active
components of neurofibromas rather than mere bystanders.
Additional evidence of active involvement of mast cells in the symptoms of NFl come
fro m clinical observations.

Rapidly growing neurofibromas are often accompanied by

inflammatory reactions such as pruritus and facial flushing (Giorno et aI . , 1989; Rothe et aI . ,
1 990).

The pruritus is not controlled with standard H I antihistamines such as
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diphenhydramine hydrochloride (Riccardi, 1 987), but the mast cell stabilizing drugs ketotifen
and disodium cromoglycate are effective (Riccardi, 1 98 1 ; Riccardi, 1 987). In some cases,
treatment with ketotifen even resulted in a decrease in neurofibroma growth (Riccardi, 1 987).
The Schwann cells of NFl tumors may also produce substances which exhibit
mitogenic activities through both autocrine and paracrine mechanisms. Autocrine and
paracrine growth factors in the supernatant ofNF I neurofibroma cultures have been reported
which could increase Schwann cell growth in vitro (Riccardi, 1 986). Nerve growth factor

(NGF) is secreted by Schwann cells, especially in the presence of gangliosides (Ohi et a!.,
1 990), and has been shown to induce mast cell proliferation (Matsuda et a!., 1 99 1 ) TGF p
messenger RNA has been detected in rat Schwann cells, suggesting that TGF p may be
produced as an autocrine growth factor by Schwann cell tumors (Ridley et a!., 1 989). In
addition, a schwannoma-derived growth factor (SDGF) has been isolated which has homology
to epidermal growth factor (EGF) and glial growth factor (GGF), and which can stimulate
proliferation of Schwann cells, fibroblasts and astrocytes (Kimura et a!., 1 990). In light of the
current evidence, it seems possible that Schwann cell-mast cell interactions are important in
the maintenance of both populations within a neurofibroma, and may make significant
contributions to tumorigenesis.

Mast cell overview
It is interesting that the first detailed description ofNF I was reported by Friedrich von
Recklinghausen, as mentioned above (von Recklinghallsen, 1 8 82), because he also may well
have been the first to describe mast cells when he recorded his observations of granular cells
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in unstained preparations of frog mesentery (von Recklinghausen, 1863). The actual credit
for establishing that mast cells were a distinct lineage, however, goes to Paul Ehrlich. He
found that granules within cells obtained from frog mesentery exhibited metachromatic
staining with aniline dyes (Ehrlich, 1878). The name he gave these cells, "mastzellen," is
derived from the German word "masten," which means "feed or fatten," because Ehrlich
believed that the intracellular granules were the result of ingestion of particles, or over
feeding. Ehrlich also noted that mast cells had a tendency to localize around blood vessels
and nerves, and in areas of inflammation or neoplasia.
Over the years, theories concerning the origin and lineage relationships of mast cells
have evolved along with advances in scientific investigation At first some thought that mast
cells arose from lymphocytes, fibroblasts or macrophages (Valent et aI. , 1989; Burnet, 1977;
Zucker-Franklin et aI., 1981; Czarnetzki et aI., 1982). Others believed they were derived from
mesenchymal cells, plasma cells, histiocytes, endothelial cells, or degenerate cells (reviewed
in Michels, 1963). The current theory is that mast cells arise from hematopoietic stem cells
in the bone marrow. Kitamura and colleagues demonstrated this using adoptive transfer
experiments involving the mast cell-deficient W/W' and Sl/Sr mice. They found that they
could cure the mast cell deficiency in W/w' mice by injecting them with bone marrow from
congenic normal littermates or from Sf/Sf' mice (Kitamura et aI., 1978). Others observed that
mast cells could be grown in vitro from bone marrow when cultured in the presence of a
variety of cell culture-conditioned media now known to contain interleukin 3 (IL-3), a growth
factor for murine mast cells (Hasthorpe, 1980; Nabel et aI., 1981; Razin et aI. , 1981; Schrader
et al., 1981; Tertian et aI., 1981;Yung et al., 1981). Both in vitro (Kirshenbaum e t al , 1991;
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McCarthy et aI., 1980) and in vivo (Fodinger et aI., 1994) studies have suggested that human
mast cells also originate in the bone marrow. Mast cells in the human are now known to arise
from CD34+ hematopoietic progenitors, but not from CD34- bone marrow cells (Kirshenbaum
et aI. , 1991).
Although it is generally accepted that mast cells originate in the bone marrow, their
relationship to other hematopoietic lineages is still unclear. Mast cells were long thought to
have arisen from the same progenitor as the basophil, because both have granules which
exhibit metachromatic staining, both contain histamine, and both express the high affinity
receptor for IgE (FccRI). Similarities between the two cell types have been observed at the
ultrastructural level as well (Zucker-Franklin, 1980). This common progenitor theory has
become less popular, however, as the current body of knowledge has grown. Mast cells and
basophils differ in nuclear morphology, granule content, location in the organism, and
response to external stimuli (reviewed in Galli and Lichtenstein, 1988; Valent and Bettelheim,
1 990). Also, mast cells leave the bone marrow as immature progenitors, completing their
differentiation in the peripheral tissues, while basophils are not released until they are fully
mature, terminally differentiated cells (McNeil, 1996). The fact that mast cells express the
transcription factors GATA- I , GAT A-2 and GATA-3 (Martin et aI , 1990a; Zon et aI., 1991)
is another point which distinguishes them from the basophil lineage. Rather, these findings
suggest that mast cells may share a common progenitor with erythrocytes and
megakaryocytes, which also express the GAT A binding proteins.

A possible relationship between mast cells and the monocyte/macrophage lineage has
also been suggested based upon the observation that human mast cells are recognized by some

19
monoclonal antibodies specific for differentiated macrophages (Valent et aI., 1989). Also,
both cell types differentiate in the periphery, and both activated macrophages and activated
mast cells produce cytokines (reviewed in Costa et aI., 1993; Galli et aI., 1991; Galli et aI. ,
1 993 ; Gordon et aI., 1990; Paul e t aI., 1993). However, Agis and others have found that
human mast cells are not derived from monocytes cultured in the presence of stem cell factor,
and suggest that the mast cell does not arise from a monocyte/macrophage precursor (Agis
et aI., 1 993). This group went on to show that mast cells developed from a peripheral blood
progenitor which was CD34+, Kit+, Ly" , CD 14" , and CD I T . These data indicate that mast
cells do not appear to originate from circulating monocytes (CD 14+), basophils (CD I r), or
lymphocytes (Ll), but demonstrate that mast cells are replenished directly from early
hematopoietic progenitors and therefore represent a unique hematopoietic cell lineage (Agis
et aI., 1 993). In spite of the advances being made in the field of mast cell biology, a specific
relationship of the mast cell to other hematopoietic lineages continues to be debated.
There is considerable structural and functional heterogeneity within the mast cell
lineage in both the human and rodent. Mast cells found in human lung and intestinal mucosa
were shown by electron microscopy to contain granules with many scroll-like crystal
structures, (Craig et aI., 1988; Weidner and Austen, 1 990). These granules contain a subclass
of tryptic serine proteases (tryptases), leading to the classification of these cells as MCT, for
"mast cell/tryptase" (Irani et aI., 1986). A second subset of mast cells is found in the
connective tissue stroma of skin, intestinal submucosa, breast parenchyma and lymph nodes,
and interacts with microvascular and neural networks. Electron miscroscopy of these cells
reveal very few scroll-like structures (Craig et aI., 1988; Weidner and Austen, 1990), and they
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have been named MCTO because their granules contain both tryptases and chymases, as well
as an exopeptidase, carboxypeptidase A (Irani et a!. , 1986). The two subsets of human mast
cells also exhibit functional differences. For instance, Mere are responsive to the complement
component CSa, morphine derivatives, and various neuropeptides, but MCT are not sensitive
to these stimuli (Cohan et a!. , J 989).
Two subsets of mast cells in rats and mice have been characterized based upon tissue
localization, T cell-derived growth factor dependence, and protease expression.

The

connective tissue mast cell (CTMC) and the mucosal mast cell (MMC) in rodents are in many
ways comparable to the MCTe and the M�. of the human, respectively. The CTMC and
MMC in the mouse can be distinguished by their differential expression of a large family of
serine proteases (McNeil and Austen, 1 994). Jarboe and colleagues have identified two types
of murine mast cell progenitors: one that is dependent upon interleukin-3 (IL-3), and another
that is not, but instead responds to a fibroblast-derived factor (Jarboe and Huff, 1989; Jarboe
et a!., J 989).

These two progenitors may give rise to MMC and CTMC, respectively

(Kobayashi et a!., 1986). There is evidence, however, that murine mast cells can change their
phenotypic characteristics in response to alterations in their microenvironment (McNeil and
Austen, 1994; Ghildyal et a!. , 1992; Gurish et a!., 1 992). Mast cells which appear to be
morphologically differentiated are long-lived, can proliferate extensively, and are able to
change their phenotype (Takagi et a!. , 1992). It may be that this ability to change phenotype
in response to environmental stimuli enables murine mast cells to adapt their functional
capabilities in response to diseases or immunologic responses. In the human system, however,
the ability of mast cells to switch from one phenotypic subset to the other has not been
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demonstrated. Some investigators have suggested that human mast cells may commit to
either the MCT or the M�c subset early and proceed upon distinct pathways (Irani et aI.,
1992; Craig et aI., 1989)
It seems that the bulk of our understanding would implicate the mast cell as an "evil 
doer" which presents itself a s a mere nuisance, a s i n those who suffer milder forms o f allergy,
or as a serious threat, as in the case of victims of anaphylaxis. The mast cell' s involvement
in type I hypersensitivity, allergic asthma and numerous intlammatOlY processes is widely
accepted (reviewed in McNeil, 1996; Galli and Costa, 1995). Moreover, there is significant
evidence that mast cells are involved in sudden infant death syndrome (Platt et aI . , 1 994).
Although logic dictates that the mast cell's evolutionary persistence implies an essential
function in normal physiology, our inability to assign functions to the mast cell that are
beneficial to the organism underlies the "riddle of the mast cell" (McNeil, 1 996; Galli, 1990).

Kit, the product oj the c-kit protooncogene
In the course of maintaining inbred strains of mice for use in research, scientists are
sometimes given the 0PPoliunity to study the functions of unidentified gene products which
have been altered in some way due to spontaneous mutations in these strains.

These

"experiments of nature" have been extremely important in our understanding of the functions
of stem cell factor (SCF) and its receptor, Kit. Much of what we now know about the
involvement of SCF and Kit in hematopoiesis and developmental programs involving
melanocytes, genn cells and mast cells was predicted based on studies with mutant mice long
before the gene products were identified.
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For a number of years it has been known that mutations at either the dominant white
spotting (W) locus on chromosome 5 or the steel (Sf) locus on chromosome 1 0 resulted in
similar phenotypic changes. These include changes in coat pigmentation, severe macrocytic
anemia, sterility, and a dramatic reduction in the number of mast cells (Kitamura et aI., 1 978;
Kitamura and Go, 1 979; Russell, 1 979; Silvers, 1 979). Following transplantation and embryo
fusion studies using W and Sf mutant mice and in vitro studies using cells and tissues from
them, it was suggested that deficits in the W mutant mice were expressed by the cells in the
affected lineages, and those in the Sf mutants were expressed by cells in the microenvironment
necessary for the development of the affected lineages (Russell, 1 979; Silvers, 1 979). The
similarities of phenotypic changes resulting from mutations at either locus suggested that the
W locus might encode a receptor expressed by the cells of the affected lineages, while the Sf
locus might encode the cognate ligand (Russell, 1 979). More recent work has confirmed that
the W locus is allelic with the c-kit gene, which encodes a receptor tyrosine kinase (Chabot
et aI. , 1 988; Geissler et aI., 1 988a, b), and that SI encodes the corresponding ligand, which
has been given several names, including stem cell factor (SCF, Zsebo et aI., 1 990a, b; Martin
et al., 1 990b), Kit ligand (KL, Huang et aI., 1 990), mast cell growth factor (MGF, Williams
et al., 1 990; Copeland et aI., 1 990; Anderson et aI., 1 990), and steel factor (SLF or SF, Witte,
1 990; Williams et aI., 1 992a).

The kit gene was first characterized as the viral oncogene v-kit of a feline sarcoma
virus (Besmer et aI., 1 986). It was later determined that v-kit arose from transduction and
truncation of the cellular protooncogene c-kit (Yard en et aI., 1 987; Qiu et aI., 1 988). The c
kit gene was first cloned in the mouse from a brain cDNA library (Qiu et aI, 1 988). The
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predicted amino acid sequence was found t o display significant homology t o members o f a
family of transmembrane receptors now known as type III receptor tyrosine kinases (RTKs),
which includes the receptor for macrophage colony stimulating factor (M C SF, encoded by
c-fms), the platelet-derived growth factor (PDGF) receptors alpha and beta (Besmer et a!. ,
1 986; Varden e t a!., 1987; Qiu e t a!. , 1988), and the more recently described receptor
Flk2/Flt3 (Lyman et a!., 1993 ).
The Kit protein contains an extracellular ligand-binding domain with five
immunoglobulin-like regions. These regions contain several intramolecular disulfide bonds
and potentialN-glycosylation sites (Yarden et a!. , 1987; Qiu et a!., 1988) The intracellular
portion of the protein contains a kinase region which is split into two parts by a noncatalytic
stretch of 77 amino acids known as the kinase insert (Yarden et a!., 1987; Qiu et a!., 1988).
It has been demonstrated in the murine system that a specific tyrosine residue within the
kinase insert (Y719) is critical for signal transduction through physical association with
phosphatidylinositol 3'-kinase (PI3 K), and that Y719 must be phosphorylated before this
association can occur (Serve et a!., 1994).
Upon binding to stem cell factor, Kit is induced to dimerize, and this dimerization
correlates with autophosphorylation and activation of its kinase (Blume-Jensen et a!., 1991;
Philo et a1., 1 996). After activation, Kit rapidly associates with specific cytoplasmic signaling
proteins involved in cell proliferation and survival, including PI3K and phospholipase C-y 1

(PLCy l) (Rouapel et a!., 1991). In contrast to the loss of Kit function observed in the
various W mutant mice, some activating mutations have been reported in both mouse and
human. The factor-independent tumorigenic murine mastocytoma cell line P8 1 S was found
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to express a constitutively tyrosine-phosphorylated Kit receptor, in the absence of endogenous
or exogenous SCF (Rottapel et a!., 1991). Furitsu and coworkers discovered that the Kit
protein in the human mast cell leukemia cell line HMC- l was also constitutively
phosphorylated in the absence of SCF. In addition, they found two point mutations in the
region encoding the cytoplasmic domain of the receptor (Furitsu et a!., 1 993). These findings
are suggestive that some activating c-kit mutations may contribute to transformation of some
cells. Nagata et a!. have identified a point mutation in the catalytic domain of Kit in patients
who have mastocytosis with an associated hematologic disorder. Identical or similar amino
acid substitutions in mast cell lines resulted in ligand-independent autophosphorylation of the
receptor (Nagata et a!., 1995).
In addition to activating mutations of the receptor, aberrant signal transduction
through Kit may result from autocrine stimulation arising either from ectopic expression of
Kit in tissues that normally express SCF, or from ectopic expression of SCF in tissues that
normally express Kit. Indeed, coexpression of the receptor and ligand has been reported in
gynecological tumors (Inoue et a!., 1994), colon tumor cell lines (Toyota et a!., 1 993), in the
majority of surgical breast tumor specimens and tumor cell lines (Hines et a!., 1995), and in
at least 70% of small cell lung carcinoma (SCLC) tumors and tumor-derived cell lines (Hibi
et aJ., 1 99 1 ). Moreover, Krystal et al. showed that transfection of a c-kit expression vector
into an SCLC line that expressed SCF but not Kit resulted in constitutive tyrosine
phosphorylation of immunoprecipitated Kit protein and more vigorous cell growth in serum
free medium compared to control-transfected cells. This group also reported that transfection
of an SCLC line which normally coexpresses SCF and Kit with a dominant negative, kinase-
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defective c-kit gene resulted i n a significant loss of growth factor independence (Krystal e t aI.,
1 996)
The phenotype of the W and SI mutant mice suggest that SCF and Kit are likely
involved in development of hematopoietic, melanoblast, and germ cell lineages in the
developing mouse embryo. Studies examining the patterns of expression of the two proteins
have confirmed this involvement in terms of the migration and spatial distribution, as well as
the proliferation and differentiation of the cells at their definitive sites in the developing
embryo (Matsui et aI., 1990; Orr-Urtregger et aI., 1990; Keshet et aI., 1991). However,
expression was also detected in tissues other than those apparently affected in the W and SI
mutants. These findings have indicated a possible role for Kit signaling in the development
of cells in the placenta, the nervous system, the septa of the heart, the lung, the facial
chondrogenic nuclei, and the midgestational kidney (Galli et aI. , 1 994) Clearly, SCF and Kit
are of vital importance in the early development of the animal. In fact, loss of function
mutations in both alleles of either locus leads to an inability to properly develop, resulting in
the death of the fetus in utero (Nocka et aI , 1 989)

Stem eellfactor
After it had been established that the W locus of the mouse was allelic with c-kil, it
was reasonable to imagine that the ligand might be encoded at SI, in accord with Russell' s
earlier proposal (Russell, 1979). Experiments using combinations o f mast cells o r their
precursors and fibroblasts derived from W or SI mutant mice provided strong biological
evidence that fibroblasts can produce membrane-bound (Kitamura et aI , 1 989; Fujita et aI. ,
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1989; Kitamura and Fujita, 1989) and soluble (Jarboe and Huff, 1989) forms of the Kit ligand.
Soon after these reports, Nocka et al. purified and characterized a mouse fibroblast-derived
factor which could stimulate growth of normal mast cells, but not mast cells derived from W
mutant mice (Nocka et aI., 1990). Later that year three groups simultaneously reported the
cloning and characterization of the growth factor (designated SCF in this review) which
represented the product of the Sf locus, and a ligand for the receptor encoded at c-kit
(Williams et aI., 1990; Copeland et aI., 1990; Anderson et aI., 1990; Zsebo et aI., 1990a, b;
Martin et aI., 1990b; Huang et aI., 1990).
Physical characterization of the SCF protein indicates that it is heavily glycosylated,
and exists as noncovalently associated dimers (Arakawa et aI., 1 991; Lu et aI. , 1991; Langley
et a1. , 1992). In the human, alternative splicing of the mRN A gives rise to two forms of SCF
protein: soluble or membrane-bound (Anderson et aI., 1991). The full-length mRNA encodes
a transmembrane protein of 248 amino acids, which includes a 25 amino acid cleaved signal
peptide, a 189 amino acid extracellular domain, which includes a membrane-proximal
proteolytic cleavage site encoded by exon 6, a hydrophobic membrane-spanning region of 2 1 23 amino acids, and a short intracellular domain of 36-37 amino acids. This form i s efficiently
cleaved by an unidentified protease and released as soluble SCF Exon 6 is not included in
the alternative SCF mRNA, which encodes a transmembrane protein that lacks 2 8 amino

acids, including those which comprise the protease recognition site (Anderson et aI., 1991).
This form is much more resistant to proteolysis and generally remains associated with the cell
membrane. Three isofonns of SCF have been reported in the mouse, including exon 6containing and exon 6-lacking forms similar to those found in the human, and a third form
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which contains a smaller 16 amino acid deletion of the exon 6 sequence. This deletion also
eliminates the protease recognition site, giving rise to a predominantly membrane-bound
protein (Anderson et aI., 1 990; Flanagan et aI., 1 991).

The transcriptional and post

translational events necessary for production of either soluble or membrane-bound SCF are
obvious points at which a given cell may regulate SCF isoform expression. The biological
effects of membrane-bound vs. soluble SCF may be significantly different (see later
discussion), as has been reported with respect to bone marrow progenitor cells (Toksoz et aI.,
1 992).
Although most functional studies of SCF have focused on the biological activities of
the extracellular portions of the proteins (soluble or membrane-bound), there is limited
evidence that the short cytoplasmic tail may have biological importance which has not yet
been defined. This is suggested by the phenotype of mice bearing a mutation designated SI' 1H,
which produces a splicing defect resulting in a cytoplasmic tail of 28 amino acids, rather than

3 6 . The phenotype of SI'7J'/SI'1H mice includes sterility in males but not in females, indicating
that some biological activity resides in the cytoplasmic tail of SCF (Brannan et aI., 1992).
SCF expression appears to be tightly regulated during mouse embryogenesis.
Examination of the genital ridges of 10-day embryos revealed a gradient of SCF expression
along the route of migration of primordial germ cells between the dorsal mesentery and the
gonad anlage. Interestingly, an inverse gradient of c-kit expression was observed, with SCF
expression highest in the genital ridge and c-kit expression highest in the dorsal mesentery.
By day 1 1 . 5 , when colonization of the gonad is completed and germ cell migration is no
longer necessary, SCF expression along the migratoIY route ceases, but remains high in the

28

gonad throughout sexual differentiation (Matsui e t aI. , 1 990; Orr-Urtregger e t aI., 1 990;
Keshet et aI. , 1 991).
In the ovary of the adult mouse, c-kit is expressed only by the oocytes (Arceci et aI.,

1 992; Orr-Urtregger et aI. , 1 990; Keshet et aI., 199 1 ) and SCF is expressed at highest levels
in the surrounding granulosa cells (Keshet et aI., 1 99 1 ).

The observed pattern of SCF

expression during sexual development supports the hypotheses of several groups that cells
lining the migratory route may guide the primordial germ cells by way of haptotaxis through
expression of membrane-bound SCF, whereas expression of SCF in the gonad anlage may
indicate a chemotactic role for soluble SCF in directing homing of germ cell precursors
(Flanagan and Leder, 1 990; Williams et aI., 1 990; Matsui et aI., 1990; Flanagan et aI., 1 99 1 ;
Keshet e t aI., 1 99 1 ). Similar haptotactic/chemotactic roles for SCF in the development of
pigmentation have been suggested by studies of SCF and c-kit expression during melanocyte
migration (Keshet et aI., 199 1 ).

SCF expression can be detected in the subdermal

mesenchymal cells of the limb buds before melanocytes begin to invade, and persists during
and after melanocyte colonization. c-kit is detected in the melanocyte precursors and remains
throughout their proliferation and differentiation (Keshet et aI., 1991).
SCF and c-kit also appear to be important in the early development of the brain.
Between gestational days 1 2 and 1 5, SCF is expressed in the floor plate of the neural tube,
followed by expression in the ventrolateral regions associated with motor neuron
differentiation (Matsui et aI., 1990; Orr-Urtregger et aI., 1990). c-kit expression has been
detected in migrating neural crest cells and in the differentiating neurons in the dorsal neural
tube and dorsal ganglia, suggesting that SCF may function as a chemoattractant for neurons
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and/or axonic processes (Keshet et a!., 1991).
Expression of c-kit is high in the embryonic liver at gestational day 1 1 . 5 , a time at
which the liver is heavily involved in hematopoiesis (Orr-Urtregger et a!., 1990; Keshet et a!.,
1 99 1 ), consistent with the widely accepted view that SCF is an important hematopoietic
growth factor. In the adult mouse hematopoietic system, c-kit mRNA expression is found
predominantly in those lineages affected by W mutations, including mast cells and early
erythroid and myeloid cell lines (Andre et a!. , 1989; Nocka et a!. , 1989) Using '2S I-labeled
SCF in binding studies, Metcalf andNicola found that Kit is widely distributed among cells
in adult murine bone marrow. They rep0I1ed expression on blasts, promyelocytes/myelocytes,
promonocytes, monocytes, eosinophilic myelocytes, eosinophils, and some lymphocytes
(Metcalf andNicola, 1991). In general, analysis of the distribution of c-kif mRNA and Kit
protein on hematopoietic cells indicates that levels of Kit are highest during early stages of
development and progressively diminish in parallel with maturation of the various
hematopoietic lineages (Papayannopoulou et a!., 1991).

The mast cell represents an

exception, in that mature mast cells continue to express the receptor and exhibit
responsiveness to SCF.
The biological consequences of SCF/Kit interactions include adhesion, chemotaxis or
haptotaxis, survival, proliferation, differentiation, and activation or modulation of secretion

(reviewed in Galli et a!., 1994). The various functions would require that the expression of
the appropriate isoform of SCF be specifically regulated, although the mechanism of this
regulation is presently unknown. The membrane-bound form would understandably be
involved in adhesion to Kit-bearing cells. Studies using cells expressing the sri allele, which
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makes only soluble SCF, have demonstrated that a membrane-associated form of SCF is
necessary for adhesion to mast cells (Flanagan et aI., 1991; Kaneko et aI., 1991; Adachi et aI. ,
1 992). Conversely, Adachi and coworkers have shown that mast cells derived from WIW
mice, which express no Kit on their surface, were greatly impaired in their ability to bind to
fibroblasts (Adachi et aI . , 1992). The same group demonstrated that Kit tyrosine kinase
activity was not necessary for adhesion to fibroblasts by using mast cells derived from W"I W"
or WI W'2 mutants, which bear Kit receptors with greatly diminished or completely absent
kinase activity, respectively (Adachi et aI., 1992). As mentioned above, it has been suggested
that membrane-bound SCF may promote attachment of mouse primordial germ cells during
embryonic development (Matsui et aI., 1991). It has also been shown that neutralizing
antibodies to Kit can inhibit the binding of human megakaryocytes to fibroblasts (Avraham
et aI., 1 992). These studies offer strong evidence that SCF and Kit can function as adhesion
molecules.
The defects in coat pigmentation, mast cell deficiency, and sterility characteristic of
W and SI mutant mice are known to reflect an impairment of the migration of cells of the
melanocyte, mast cell, or germ cell lineage during embryonic development (Russell, 1979;
Silvers, 1 979; Kitamura, 1989). Upon identification of the proteins encoded at these loci, it
was reasonable to assume that this migration may be due to a chemotactic response of the Kit
bearing cells to SCF. It has been shown that subcutaneous injections of recombinant SCF into
the skin of SI/Sf mice, which ordinarily lacks mast cell precursors and mature mast cells
(Kitamura and Go, 1979; Hayashi et aI., 1985), resulted in the appearance of large numbers
of mast cells at the site of injection (Zsebo et aI., 1990b; Tsai et aI., 1991). In vitro studies
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have demonstrated that porcine aortic endothelial cells transfected with wild-type human c-kit
cDNA exhibited chemotactic responses to concentrations of recombinant human SCF as low
as 50 pg/mJ (Blume-Jensen et aI., 1991). It was further shown that Kit tyrosine kinase activity
was necessary for chemotactic responsiveness to SCF (Meininger et aI., 1992).
Given the fact that certain Kit-expressing cells, such as oocytes, melanocytes, and
mast cells are able to reside in the tissues for long periods of time without undergoing
proliferation, one might imagine that SCF is involved in promoting their survival. There are
several lines of evidence that support this theory, and that suggest that the membrane
associated form of SCF is responsible. When normal mast cells were injected into the dermis
of Sf/Sf mice, which lack membrane-bound SCF, they did not survive (Gordon and Galli,
1 990). However, the mast cells did survive when injected into the skin of W'/W" mice,
suggesting that membrane-bound SCF is necessary for, or at the least, more effective than
soluble SCF for promoting the survival of mast cells (Gordon and Galli, 1 990) Toksoz et al.
demonstrated that the membrane-bound form of SCF maintained hematopoiesis for longer
periods than the soluble form (Toksoz et aI., 1992). Although membrane-bound SCF is better
at maintaining the survival of mouse primordial germ cells in vitro (Dolci et aI., 1991; Matsui
et aI., 1 991), it has been shown that soluble SCF can also maintain the survival of mouse
primordial germ cells (Dolci et aI., 1991; Godin et aI , 1 991; Matsui et aI , 1991),
hematopoietic stem cells (Bernstein et aI , 1991; McNiece et aI , 1991; Metcalf andNicola,
1991 ; Tsuji et a1., 1991; Cicuttini et aI., 1992; Migliaccio et aI, 1992; Williams et aI., 1992b),
human melanocytes (Funasaka et aI., 1992), human mast cells (Irani et aI., 1992; Valent et aI ,
1 992; Mitsui et aI, 1993), or human NK cell precursors (Uittenbogaart et aI, 1992) in vitro,
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and can promote the survival o f mouse mast cells in vitro o r i n vivo (Zsebo et aI . , 1 990b; Tsai
et aI., 1 99 1 ) . In addition, Iemura and others have provided evidence that SCF promotes the
survival of mast cells by suppressing apoptosis (lemura et aI . , 1 994) .
An in vitro mast cell proliferation assay has been the standard bioassay for

characterizing SCF bioactivity since the cloning of the gene (Williams et aI . , 1 990; Copeland
et aI. , 1 990; Anderson et aI., 1 990; Zsebo et aI . , 1 990a, b; Martin et aI . , 1 990b; Huang et aI . ,
1 990). There can b e little argument about the ability o f SCF t o induce proliferation i n mast
cells. However, the effects of SCF on the proliferation of other Kit-bearing lineages is most
dramatic in the context of synergism with other stimuli (reviewed in Galli et aI . , 1 994). SCF
is much more effective in inducing proliferation of cultured mouse primordial germ cells when
leukemia inhibitory factor (UF) is added as a cofactor (Matsui et aI . , 1 99 1 ) .

Human

melanocytes proliferate ill vitro when SCF is provided with PMA, but SCF alone has little
effect (Funasaka et aI . , 1 992) .

Similarly, SCF by itself has only modest effects on the

development of colonies of hematopoietic cells ill vitro, but acts in synergy with many other
growth factors to promote the production in vitro of early and intermediate precursors of
erythroid, myeloid, and lymphoid lineages (Galli et aI . , 1 994).
Finally, SCF can function as an agent to stimulate mediator release from mast cells
through Kit signaling. SCF-induced mediator release has been demonstrated in purified
human skin mast cells (Columbo et aI . , 1 992) and from purified mouse peritoneal mast cells
(Coleman et aI. , 1 993) in vitro. In addition, ill vitro studies with human lung (Bischoff and
Dahinden, 1 992) or skin (Columbo et aI . , 1 992) mast cells or with purified mouse peritoneal
mast cells (Coleman et aI., 1 993) also showed that soluble SCF can enhance the level of mast
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cell secretion and mediator release observed i n cells stimulated through the high affinity IgE
receptor (FcERI). This effect was seen at SCF concentrations substantially lower than those
required to induce mediator release directly. Taken together, these data indicate that SCF is
involved in mast cell development and function. It is not clear to what extent SCF may also
influence the functional activity of other lineages that express Kit.

Materials and Methods

Animals

Female BALBlc mice, 8- 1 0 weeks of age, were purchased from the National Cancer
Institute, Frederick, MD . They were maintained in laminar flow housing and provided with
food and water ad libitum.

Antibodies
An affinity-purifi e d rabbit IgG polyclonal anti-human c-kil antibody raised against a

synthetic peptide (American Research Products, Inc., Belmont, MA) was the primary antibody
used for immunohistochemistry. Control experiments were performed using rabbit IgG
purified from serum of non-immunized animals (Jackson Immunoresearch Laboratories, Inc . ,
West Grove, PA). Immunofluorescent staining was done with a monoclonal anti-human c-kil
antibody (clone l .D9.3D6, B oehringer Mannheim Biochemica, Indianapolis, IN)

Non

specifi c interactions were blocked with a solution containing purifi e d human IgG (Jackson) .
A mouse IgGJ (Biosource International, Camarillo, CA) was used as a negative control. In

the immunofluorescence studies, anti-c-kit antibodies were localized using a biotin-conjugated
F(ab')2 goat anti-mouse IgG (Jackson), followed by fluorescein isothiocyanate (FlTC)-labeled
streptavidin (Pierce, Rockford, IL) .
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Cells and eell lines

The murine fibroblast cell line BALBlc 3T3, the human fibroblast lines CCD 1 8, HS68
and MRC-9, and the human fibrosarcoma cell line HT 1 080 were all obtained from American
Type Culture Collection, Rockville, MD . The four human malignant schwannoma cell lines
were generous gifts of Dr. George DeVries, Department of Cell Biology, Neurobiology and
Anatomy, Loyola University, Chicago, IL. The ST88- 1 4 line was derived from a peripheral
nerve sheath tumor of a patient diagnosed with NF I (Fletcher et aI, 1 99 1 ), and partially
described elsewhere (DeClue et aI , 1 992; Reynolds et aI , 1 992). Due to contamination of
this line, a separate clone was obtained directly from Dr. Jonathan Fletcher, Department of
Pathology, Brigham and Women's Hospital, Boston, MA. Other malignant schwannoma cell
lines include the STS-26T line, which was derived from an isolated grade III malignant
schwannoma in a patient who did not have NF l (Dahlberg et aI , 1 993), the NF- I T cell line,
derived from a malignant soft tissue sarcoma in an NF l patient (Dahlberg et aI , 1 993), and
the T265-2c cell line, which was established in the laboratory of Dr. George DeVries from a
malignant schwannoma in a patient with NF I . The HMC- I cell line was derived from a
p atient with mast cell leukemia, and was the kind gift of Dr. Joseph H. Butterfield, M . D . ,
Allergic Diseases and Internal Medicine, Mayo Clinic, Rochester, MN. A l l cells except HMC1 were maintained in Dulbecco' s modified Eagle ' s medium supplemented with 2mM L

glutamine, 5 0/-lg/ml gentamicin, 1 00U/ml penicillin, 1 00/-Ig/ml streptomycin, and 1 0% fetal
calf serum (cDMEM) in a humidified chamber at 3 r C and 5% CO 2 . HMC- I cells were
grown in Iscove's modified Dulbecco' s medium with 1 0% defi n ed, iron-supplemented bovine
calf serum (Hyclone Laboratories, Logan, Utah), 1 . 2mM monothioglycerol (Sigma Chemical
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Company, St. Louis, MO), 2mM L-glutamine, 50�g/ml gentamicin, 1 00U/ml penicillin, and
l OO�g/ml streptomycin at 3 7 " C and 5% CO 2 .
Total RNA was extracted from surgical tissue and cultured cells in this laboratory
using the Ultraspec™-II RNA isolation system (Biotecx Laboratories, Inc, Houston, TX),
which involves extraction with acid guanidinium thiocyanate and phenol-chloroform
(Chomczynski and S acchi, 1 987) .
Primary human fi b roblast cultures designated 8N, Edwards, 1 6BN, and 3 0K were
established and maintained in the laboratory of Dr. Dome Yager (Division of Surgery,
Department of Medicine, Virginia Commonwealth University, Richmond, Virginia), who
kindly provided total RNA samples extracted from the cells. RNA specimens from the small
cell lung cancer cell lines H 1 46, H209, H249, and WBA, and from the breast cancer line
MCF7, were the generous gifts of Dr. Geoffrey Krystal (Division of HematologyIOn co logy,
Department of Medicine and Department of Microbiology and Immunology, Virginia
Commonwealth University and McGuire VA Medical Center, Richmond, V A).

Cytokines and growth factors

Recombinant mouse interleukin-3 (rmIL-3) and recombinant mouse stem cell factor
(nnSCF) were purchased from BioSource International, Camarillo, CA. Recombinant murine

stem cell factor used in the in vivo experiments involving intraperitoneal injections (rmSCFI69)
was cloned and expressed in this laboratory (see below) .
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Cloning, expression, and purification of rmSCP69

The production of recombinant mouse SCF l 69 was accomplished by Dr. Julie Leftwich,
a postdoctoral fellow in this laboratory, and has not been reported elsewhere. Therefore, the
protocol used is briefly stated here. A clone of mouse SCF was obtained by screening an NIH
3T3 cDNA library in a Lambda Zap II vector (Stratagene, La Jolla, CA) with a 5' end-labeled
3 0 base o ligonucleotide probe (nucleotides 25 1 -28 1 ) derived from the published sequence
(Zsebo et al. , I 990b). Nitrocellulose filters lifted from the library were incubated for 1 8 hours
at 3 7 ° C with 1 06 cpm/mJ of probe. The filters were washed 4X at 3 7 " C for 10 minutes with
2X S SC, 0.2% sodium dodecyl sulfate (SDS), followed by one wash at 5 0 ° C for 30 minutes
with 0.5X S SC, 0.2% SDS. I of 3 positive clones was chosen from 1 06 original plaques, and
in vitro excision using the R408 helper virus was performed. The resulting pBluescript

phagemids containing the cDNA were transfected into XL- I Blue host cells. The clone was
sequenced using the Sequenase Version 2 kit (United States Biochemical, Cleveland, OH) and
the coding gene region was found to have identical predicted peptide sequences as those
published (Zsebo et aI. , 1 990b).
To express recombinant SCF proteins, BglII-BSU3 6I fragments encoding the secreted
form of SCF were subcloned into PET- 3 d utilizing a 5' linker adding an Ncol site and a start
codon and a 3' linker adding a stop codon and a BamHI site. These manipulations placed the
coding region under the control of a T7 promoter which is inducible by the addition of
isopropylthiogalactoside (IPTG) . The expressed mRNA encodes a protein 1 69 amino acids
long, and has been designated rmSCFI69.
To purify rmSCFl69 protein, expression vector-containing bacteria were grown at
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28 ° C i n LBlMglglucoseJamp to an OD600 of 0.6-0 . 8 at which time IPTG was added t o a final
concentration of 0 . 8 mM. The cells were cultured an additional 2 hours, pelleted, and
resuspended in lysing buffer. The cells were then subjected to French Press (PSI

=

20,000)

and the supernatant was clarified and partially purified using sizing chromatography. The
resulting preparations of recombinant SCF proteins were approximately 80-90% pure.

Surgical specimens

Formalin-fixed, paraffin-embedded neurofibroma specimens were obtained from Dr.
Audrey Steck (Division of Pathology, Department of Medicine, Virginia Commonwealth
University, Richmond, VA). Additional neurofibroma tissue was generously provided by Dr.
Fu-Tong Liu (Division of Allergy, La Jolla Institute for Allergy and Immunology, S an Diego,
CA) . Prepared sections of formalin-fixed, paraffin-embedded malignant peripheral nerve
sheath tumors were the kind gifts of Dr. David Viskochil (Division of Medical Genetics,
University of Utah, Salt Lake City, UT). Fresh surgical specimens of vestibular schwannoma,
acoustic neuroma, and meningioma tissues were kindly provided by Dr. William Broaddus
(Division of Neurosurgery, Department of Medicine, Virginia Commonwealth University,
Richmond, VA).

Bone marrow-derived murine mast cells

Mouse bone marrow cells were obtained by flushing femurs with a 22 gauge needle
into 10 ml of cDMEM supplemented with 5 0 nglml recombinant mouse stem cell factor
(rm S CF, BioSource International, Camarillo, CA) and 50 U/ml recombinant mouse
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i nterleukin-3 (rmIL-3 , BioSource). The cells were initially maintained i n a 2 5 cm 2 tissue
culture flask in a humidified chamber at 3 r C and 5% CO 2 , After overnight incubation, the
non-adherent cells were transferred to a fresh 25 cm2 flask and placed back into the incubator,
while the adherent cells were discarded. After the second night of incubation, the cell
suspension was removed and centrifuged. The medium was discarded and the cell pellet was
resuspended in a 75 cm2 tissue culture flask in 30 ml of cDMEM supplemented with rmS CF
and rrnIL-3 at the above concentrations. The culture was maintained for a total of 4 weeks,
with non-adherent cells being removed, centrifuged, and resuspended in fresh medium every
3 -7 days.

Conditioned media from Schwann cells of NFl-deficient mice

S chwann cell-conditioned media from wild type and NFl -deficient mice were the
generous gifts of Dr. Nancy Ratner (Department of Cell Biology, Neurobiology and Anatomy,
College of Medicine, University of Cincinnati). Schwann cell cultures were established from
excised peripheral nerve tissue of embryonic C5 7BLl6 mice bearing a targeted mutation of
the NFl gene on either one (+/-) or both (-/-) alleles. Schwann cells derived from wild-type
(+/+) mice were used for comparison.

Murine mast cells grown in Schwann cell-conditioned media

Mouse bone marrow-derived mast cells, after three weeks of culture in rmSCF and
rmIL-3 (see above) were seeded onto a 96-well tissue culture plates at a density of 5
cells/ml ( 1 0 5 cells/well) in cDMEM.

x

1 05

The media in various wells contained either no
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conditioned medium (control), 1 0% conditioned medium from cultures of B ALB/c 3T3
fibroblasts (FCM), 1 0% conditioned medium from cultures of S chwann cells derived from
wild type C5 7BLl6 mice (NFl +1+ SCCM), 1 0% Schwann cell-conditioned medium from
mice which were heterozygous for a disruption in the NFl gene (NF l +1- SCCM) (Jacks et
aI . , 1 994), or 1 0% Schwann cell-conditioned medium from homozygous NFl "knockout"
mice (NFl -1- SCCM). Each of these categories included media supplemented with either 5 0
nglml rmSCF, 50 Vlml rmIL-3 , both factors, or n o added factors. After 4 - 7 days of culture
under these conditions, representative plates were examined for mast cell granule phenotype,
as determined by alcian blue/safranin staining (see below), and rate of proliferation, assessed
by 3H-thymidine incorporation (see below).

A lcian bluelsafranin staining of murine mast cells

P artial phenotypic characterization of bone marrow-derived murine mast cells was
accomplished using a two-step staining protocol (Enerback, 1 966). Cells were transferred
to slides using a Cytospin 2 (Shandon, Inc., Pittsburgh. PA) . Preparations were first covered
with 0.5% alcian blue in 0.3% glacial acetic acid for 5- 1 0 minutes, rinsed with tap water, and
covered with 0 . 1 % safranin in 0 . 1 % glacial acetic acid for an additional 5 - 1 0 minutes. The
slides were again rinsed with tap water and air dried, and coverslips were mounted using

Cytoseal™ 60 (Stephens Scientific, Riverdale, NJ). Heparin, which can be found in the
secretory granules of cells of the connective tissue mast cell (CTMC) phenotype, retains the
safranin stain, resulting in the appearance of pink or red granules. Mucosal mast cells (MMC)
do not contain heparin, and they stain alcian blue positive.
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Proliferation assays for mast cells and Schwann cells

Cultures of mast cells and S chwann cells grown in 96-well plates were "pulsed" by
addition of 1 �Ci of 3H-thymidine (lCN Pharmaceuticals, Inc., Costa Mesa, CA) to each well,
followed by continued incubation for 4-24 hours. The samples were collected onto glass fiber
filters using a Filtermate 1 96 Harvester (Packard, Meriden, CT), and the amount of 3H_
thymidine incorporation was determined using the TopCount scintillation counter (Packard).
The level of incorporation is proportional to the rate of proliferation of the cells in the sample.

Immunofluorescence for the detection of Kit on malignanl schwannoma cell lines

Each of four human malignant schwan noma cell lines, and the KEL-FlB human
fibroblast line (negative control) were cultured at low density on 2-well chamber slides (Nunc
I nc . , Naperville, IL) in cDMEM until firmly attached. The non-adherent HMC- I cell line
(positive control) were grown in a tissue culture flask and then transferred to slides using a
Cytospin 2 (Shandon, Inc . , Pittsburgh, PA). All specimens were fixed by immersion in
acetone for 1 5 minutes at _20 ° C, drained, rinsed in deionized water and dried. 500�1 of
blocking solution (1 % B SA, 1 00mM Tris pH 7.4, 1 5 0mM NaCI) containing I O�g/ml human
IgG were added to each chamber, and slides were incubated at 4 ° C for 30 minutes. The
blocking solution was removed and replaced with blocking solution containing either 20�g/ml

anti-human c-kit or IgG, isotype control antibodies, followed by incubation at 4 ° C for 20
hours. S lides were washed 3 times in wash solution ( l OOmM Tris pH 7.4, 1 5 0mM NaCI) for
1 0 minutes each. 0 . 5 ml of a I : 5 00 dilution of a biotinylated F(ab ' ), goat anti-mouse IgG in
blocking solution was added to each slide for I hour at 4 ° C . Slides were again washed three
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times in washing solution, and then incubated one hour in O . Sml of blocking solution
containing a I 1 000 dilution of streptavidin-FITC at 4 ° C in the dark . Coverslips were placed
on the slides using 5% N-propyl gallate (Sigma Chemical Company, St. Louis, MO) to
prevent quenching. S lides were analyzed on the Meridian Ultima confocal interactive laser
cytometer (Meridian Instruments, Inc., Okemos, MI).

Immunohistochemistry to detect Kit ill neur()fibroma and malignant schwannoma lissue

Immunohistochemical staining for human Kit was performed using standard
techniques.

Briefly, slides containing formalin-fixed, paraffin-embedded tissue sections were

deparaffinized in xylenes and rehydrated in a series of graded ethanol washes. Endogenous
peroxidase activity was blocked with 0 . 3 % H2 0 2 in methanol. A polyclonal rabbit anti-Kit
antibody was used as the primary antibody at a concentration of O . 5 11 g/m I. This antibody was
then localized using the Vectastain Elite Kit

(Vector Laboratories, Burlingame, C A) .

Diaminobenzidine (Vector Laboratories) was used a s the color substrate.

Quantitative reverse transcription polymerase chain reaction of mouse SCF

A quantitative RT-PCR protocol was developed which requires the use of a specially
designed "cRNA control fragment" in competitive reactions with RNA isolated from the cells
under study. This cRNA controls for variations during reverse transcription, and serves as
an internal standard for the polymerase chain reaction. A murine stem cell factor control
fragment was constructed by inserting a 1 02 base pair piece of double-stranded ON A into our
m S CF clone.

The insert was obtained by digesting the plasmid pBluescript II SK+
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(Stratagene Cloning Systems, La Jolla, CA) with the restriction enzymes KpnI and S stI. The
products were separated by agarose gel electrophoresis, and the band corresponding to the
1 02 bp fragment was cut from the gel and minced with a razor blade. The DNA was
extracted from the agarose by adding phenol, vortexing for 3 0 seconds, and incubating in a
dry ice and ethanol bath for 5 minutes. After centrifugation, the fragment was precipitated
fro m the aqueous phase by addition of 3M sodium acetate and 95% ethanol, followed by
overnight incubation at minus 20 ° C .
Our mouse S C F clone was digested with NsiI, which cuts a t a single site within the
SCF sequence (nucleotide 492 by the numbering of Anderson, et ai , 1 990), but does not cut
the vector (pBluescript II SK+). This plasmid and the insert fragment were blunt-ended with
T4 DNA polymerase.

Both samples were then incubated with calf intestinal alkaline

phosphatase (ClAP) to remove 5' phosphate groups, followed by phenol-chloroform
extraction and ethanol precipitation. A blunt end ligation was performed using T4 DNA
ligase at a plasmid: insert ratio of I : 1 00 .
E. coli XL I blue bacteria were made competent for transformation by incubating in

cold 1 00 m M CaCl2 for 1 0 minutes on ice. Cells were transformed by treatment with DM S O
an d addition of t h e products o f t h e ligation reaction, followed b y 3 0 minutes incubation on
ice. Bacteria were heat-shocked by incubating in a 42 ° C water bath for 90 seconds, and then

chilled on ice. Bacteria were grown in Luria broth (LB) containing no antibiotics for an hour
in a 3 7 " C shaker. Samples were then streaked onto LB agar plates containing ampicillin and
incubated at 3 7 " C overnight. Colonies were plucked and subcultured in liquid LB containing
ampicillin and incubated overnight at 3 r C with shaking.
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Plasmid DNA was extracted from the bacterial cultures using the Insta-Prep Kit (5'
to 3 ', Inc., B oulder, CO).

Samples were digested with the restriction enzyme XhoI to

determine if an insert had been ligated into the plasmid. The vector, pBluescript II SK+,
contains a single XhoI site. The 1 02 base pair insert also contains this site. If the insert is
missing, the enzyme cuts at only one site. If it is present, two sites are cut, releasing a
fragment of 5 94 base pairs. A clone containing the insert was chosen, and submitted to the
MCV Molecular Biology Core Facility for large-scale plasmid preparation. The cRNA was
generated by in vitro transcription using T7 RNA polymerase. The control fragment contains
the same primer binding sites as natural SCF mRNA, but will generate an RT-PCR product
which is 1 02 base pairs larger.
For competitive RT -PCR, decreasing amounts of control fragment RNA of known
concentrations are added to a series of tubes containing a constant amount of total cellular
RNA. Standard reverse transcription and polymerase chain reactions are carried out, resulting
in competition between the two templates for primers and other reaction components.
Following amplification, the products are resolved by agarose gel electrophoresis and
subjected to Southern blot analysis (see below) . The intensities of the bands on the resulting
auto radiograph are compared by densitometry.

The quantity of mRNA in the original

unknown sample is ascertained by determining the amount of control fragment needed to
generate a band of equal intensity.

Reverse Transcription Polymerase Chain Reaction (R T-PCR)

The standard RT-PCR protocols used in this study were performed using the
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GibcoBRL Superscript Preamplification System (Life Technologies, Inc. , Baltimore, MO),
supplemented with AmpliTaq® DNA Polymerase (Perkin Elmer, NOIwalk, CT).
The reverse transcription reaction was carried out by adding I llg total RNA in a
volume of J ill to a reaction tube containing 1 0 111 Milli-Q water. After addition of I IlI of a
21lM gene-specific antisense oligonucleotide primer, the mixture is incubated at 70 ° C for 1 0
minutes and then quickly chilled o n ice for at least I minute. 7111 of a master mix containing
2111 l OX peR buffer, 2111 25mM MgCI2 ' I Il I 1 0mM dNTP mix and 2111 0 1M DTT are added
to each tube, followed by a 5 minute incubation at 42 ° C . After addition of I IlI (200U) of
SuperS criptTM II RNase H- reverse transcriptase, the 42 ° C incubation is continued for an
additional 50 minutes. The reaction is terminated by incubating at 70 ° C for 1 5 minutes.
After another quick chill on ice, the contents are collected by brief centrifugation, followed
by the addition of J ill (2U) E. coli RNase H and a 20 minute incubation at 3r c .
The polymerase chain reaction was performed b y first adding 2111 o f each R T reaction
to a fresh tube. 23 111 of a master mix containing 1 8 111 water, 2 . 5 11 1 l OX PCR buffer, l . 5 1l1
MgCI" and l . 01l1 1 0mM dNTP mix are added to each reaction.

One paraffin bead

(Ampliwax® PCR Gem 1 00 [Perkin Elmer] or equivalent) is added to each tube, followed by
a 5 minute i ncubation at 80 ° C to melt the wax. After allowing the paraffin to reharden at
room temperature, 2 5 111 of a master mix containing 1 8 . 5 11 1 water, 2 . 5 111 l OX PCR buffer,
l . 5 1l1 2 5 mM MgCI" l . 01l1 J OIlM sense primer, l . 01l1 1 0ilM antisense primer, and 0 . 5 11 1
(2. 5 U) AmpliTaq® DNA Polymerase were added onto the t o p o f the wax barrier.
The PCR reactions were carried out in the GeneAmp® PCR System 9600 (Perkin
Elmer) using programs optimized for the primers and templates being used . For mouse stem
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cell factor, 3 0 cycles were performed as follows: denature at 94 ° C for 1 5 seconds, anneal at
5 5 ° C for 15 seconds, and extend for 3 0 seconds at n ° e . Reaction products were resolved
by agarose gel electrophoresis. For most applications, a standard 1 % agarose gel was used,
but for quantitative RT -PCR reactions, 4% NuSieve® 3 : I agarose (FMC BioProducts,
Rockland, ME) was used to better resolve fragments with small size differences. Bands were
visualized by staining with ethidium bromide and viewing on a UV light box.

Southern blotting

After agarose gel electrophoresis, gels were soaked for 40 minutes in a denaturing
solution containing 1 . 5M NaCI and 0 . 5M NaOH. Gels were then soaked two times (3 0
minutes each) in a neutralizing solution containing 1 . 5M NaCI and 1M Tris pH 8 . 0 . Nucleic
acid transfer was accomplished by downward capillary action as follows: a piece of thick filter
p aper, cut to gel size, was soaked 20 minutes in l OX SCC and placed on a 5 inch stack of
paper towels in a basin. This was followed by 2 pieces of thin filter paper (also cut and
soaked), a piece of O.2�m Nytran® (Schleicher and Schuell, Keene, NH), the gel (soaked 1 0
minutes in l OX S SC), a third piece of thin filter paper, and a sponge soaked in l OX S S e . The
entire container was wrapped in plastic wrap and left undisturbed overnight . After transfer,
the orientation of the wells were marked on the nytran with a needle, and the DNA was cross
linked to the Nytran using a UV Stratalinker™ 1 800 (Stratagene, La Jolla, CA).
Oligonucleotide probes were labeled using the GibcoBRL 5 ' end labeling kit (Life
Technologies, Inc., Baltimore, MO). 1 00ng of probe in 1 7�1 water were mixed with 2 � 1 T4
kinase ( I OU), 6�1 l OX forward reaction buffer, and 5 � 1 [y_32p]ATP ( i 5 0�Ci/�I). After
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incubating at 37"C for one hour, the reaction was terminated by incubating for 10 minutes at
65 ° C . The labeled probes were then hybridized to the blots using a Hybaid hybridization
oven (Hybaid Instruments, Holbrook, NY). The Nytran fi l ters and nylon mesh were briefly
soaked in sterile water, layered upon each other, rolled into a tube and placed in a
hybridization bottle. A 2X prehybridization solution was prepared by mixing l 25mg yeast
RNA (mixed in I ml water and a few drops of NaOH), 2 . 5 ml 20% SDS, 0 . 5 g bovine serum

albumin, 0 . 5 g polyvinylpyrrolidone (PVP), 0 . 5 g ficoll, 25ml 1M sodium phosphate pH 6 . 5 ,
and 1 25ml 20X S SC, brought t o a total volume o f 250m I with water. 1 0mi o f a 1 . 1 mixture
of2X prehybridization solution and water were added to the bottle containing the blots, and
the bottle was incubated in the hybridization oven for 1 hour at 3 7 " C . This solution was then
poured off and replaced with fresh 1 . 1 prehyb mix and water to which the entire probe
labeling reaction was added. The blots were incubated with the probe overnight in the oven
at 3 7 " C . After disposing of the solution into the appropriate radioactive waste container, the
blots were washed twice ( 1 0 minutes each) in 3 0ml of2X S S C/O. I % SDS at 3 7 " C, followed
by a 1 hour wash in 50ml of O.2X S S C/O. I % SDS at 3 7 ° C . The excess liquid was blotted
from the filters with paper towels, the blots were covered in plastic, and placed on x-ray film
for 24 hours (exposure time varies with the strength of the signal).

Ribonuclease protection assay (RPA) for SCF iso/arms

Total RNA was obtained by using the UItraspec™ RNA isolation system (Biotecx
Laboratories, Inc . , Houston, TX) . Samples were stored at -80 ° C at concentrations of 1 -2
� g/ � I until needed . The probe was generated by PCR amplification of a fi'agment of our
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cloned human stem cell factor cDNA (Ryan e t aI , 1 994) including most of exons 5 a n d 6
(nucleotides 560-78 1 as numbered by Martin et aI , 1 990) . The following primers were used
Primer I : 5'-ATGGGATCCATTCAAGAGCCCAGAAC-3 '; primer 2 5'-GCTCTAGA TGC
TACTGCTGTCATTCC-3 '. Nucleotides in bold type represent restriction sites for BamHI
and Xbal, respectively. After amplification, the fragment was digested with the two enzymes
and ligated into pBluescript II SK+ (Stratagene Cloning Systems, La Jolla, CA), which had
been similarly digested. A radiolabeled transcript was obtained with the MAXIscriptTM In
Vitro Transcription Kit (Ambion, Inc . , Austin, TX) using T3 RNA polymerase and [a_·n p]
UTP . RNase Protection Assays (RPA) were performed with the RPA JITM kit (Ambion),
following the suggested protocol Fragments were resolved on a 5% acrylamide 8M urea
sequencing gel Protected fragments of 222 and 1 44 nucleotides are indicative of the exon
6-containing (soluble) and exon 6-lacking (membrane-bound) isoforms of human S CF mRNA,
respectively.

ELISA for human SCF

Conditioned media were assayed for immunoreactive stem cell factor using a
Quantikine™ human SCF kit (R&D Systems, Minneapolis, MN). The kit contains all the
necessary antibodies and standards, and the manufacturer' s suggested protocol was followed.
The plates were read at 450 nm on a V-max Kinetic Microplate Reader (Molecular Devices
Corp . , Palo Alto, CA) . The range of the assay was from 3 1 . 25 to 1 000 pglml

Results

In vivo effects of intraperitoneal injections of rmSCF'69

To determine if intraperitoneal SCF injections might lead to the migration of mast cell
precursors into the peritoneal cavity and subsequent maturation and proliferation, mast cells
in the peritoneum were quantitated. Mice were given daily intraperitoneal injections of 3 �g
ofrmSCF 1 69 in 1 00 �I sterile phosphate-buffered saline (PB S). A control group was inj ected
daily with PBS alone. After 16 days of injections, a group of SCF-treated mice and a group
of control mice were infected with the hookworm Nippostrongylus brasiliensis (Nb) by
subcutaneous injection of 600 stage 3 larvae/mouse in 200 �I PBS . Mice were sacrificed after
22 days of SCF (or PBS) injections. In Nb-infected animals, this corresponded to day 7 post
infection. Five ml of a 0 . 22 M sucrose solution were injected into the peritoneal cavity,
followed by gentle massage to dislodge cells. After the muscle membrane lining the cavity
was surgically exposed, the fluid was removed with a Pasteur pipette through a small hole in
the membrane. The cells in these samples were transferred to slides with a Cytospin 2
cytocentrifuge, and stained with acid toluidine blue to detect mast cells. Although peritoneal
wash-out cells such as these are a rich source of mature mast cells in untreated mice, the
numbers were markedly decreased in response to SCF treatment (Figure I ). As previously
reported, peritoneal mast cell numbers were also greatly diminished in response to Nb
infection alone (Huff et aI. , 1 995).
49
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Figure 1 . Effects of rmS CF l 69 inj ections o n peritoneal mast cell numbers. Mice were given
daily intraperitoneal injections of PB S alone or 3 ).Ig of rmSCF l 69 in PB S for 22 days, at which
time the mice were sacrificed. Nb infection was established by subcutaneous inj ection of 600
stage 3 larvae of the hookworm Nippostrongy/us brasiliensis seven days prior to sacrifice.
Cytospin preparations of peritoneal washouts were stained with 0.2% acid toluidine blue, and
mast cells were enumerated. Data represent the mean ± SEM of mast cell counts in five
random 20X microscopic fields from three mice.
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Next w e wished to determine i f mast cell numbers might be systemically affected.
Subcutaneous injections of SCF have been shown to result in a local mast cell hyperplasia at
the site of injection (Zsebo et a!. , 1 990b; Tsai et a!. , 1 99 1 ) . We tested to determine if
prolonged intraperitoneal inj ections of high doses of rmSCF1 69 would lead to a systemic
increase i n mast cell numbers. Mice were sacrificed and five ml of air were injected
subcutaneously into the back skin of mice just over the spine. The back skin was then everted
to reveal a transparent bubble of dermal tissue. This tissue was dissected away and dermal
spreads were prepared on slides. After air drying, the slides were stained with 0 . 2% acid
toluidine blue and the mast cells were counted. No significant difference in the number of
mast cells was observed between control and SCF-treated subjects after 22 days of inj ections
(and 7 days ofNb infection, where applicable), suggesting that intraperitoneal administration
of high doses of SCF does not appear to cause a systemic mast cell hyperplasia (Figure 2).
Having demonstrated that mast cell numbers were locally but not systemically
decreased, we wished to determine if intraperitoneal SCF treatment might affect Nb egg
production and worm expulsion. The degree ofNb infection in control and SCF-treated mice
was monitored by performing daily fecal egg counts on days 4- 1 1 following larval inj ections.
To do this, we collected feces by housing the mice in wire bottomed cages. Fecal droppings
were collected on moist paper towels, retrieved, and eggs were counted using the OvassayTM
fecal diagnostic system (pitman-Moore, Inc . , Mundelein, IL). The results of this experiment
are shown i n Figure 3 . No significant differences were noted in the number of Nb eggs
expelled by either PBS control or SCF-injected animals. As an alternative means to determine
the severity of infection, adult Nb worms in the small intestines of mice sacrificed on days 7
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Figure 2 . Effects of rmSCF169 injections o n dermal mast cell numbers. rmSCF169 inj ections
and Nb infections were performed as in Figure I legend. Dermal tissue was obtained by
injecting a 5 ml air bolus under the skin just over the spine. S kin was surgically everted, and
the membranous dermal tissue was excised and placed on slides. After air drying, the slides
were stained with acid toluidine blue. Data represent the mean ± SEM of mast cell counts in
5 random 20X microscopic fields from 3 mice.

54

Dermal m a s t cells

12

10
'0

0;
l.::
><:

8

<:>

�0;
'-'
....
'"
..

�

6

4

2

0

PBS only

Nb only

SCF only

7 days post Nb infection

Nb + SCF

55

Figure 3 . Effects ofnnSCF169 injections o n severity of Nippostrongylus brasiliensis infection :
fecal egg counts. Nb-infected mice were housed in wire-bottomed cages, and fecal droppings
were collected every 24 hours for the indicated days. Nb eggs were counted using a
commercial fecal diagnostic kit. Data represent the mean ± SEM of counts obtained from
triplicate test subjects. Injections and Nb infections were performed as described in Figure
1 legend.
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and 1 6 post infection were counted. The small intestine ( 1 5 c m section) o f each mouse was
removed and opened using surgical scissors. The worms were counted using a dissecting
stereomicroscope either directly in the gut section, or as a suspension in PB S . As seen in
Figure 4, a large number of worms were observed in the gut of both control and SCF-treated
mice after 7 days ofNb infection, and the worms were completely cleared in both groups by
day 1 6. This time course is consistent with previous results in our laboratory using this model
system. Stem cell factor injections did not appear to have any effect on the number of worms
in the small intestine, or on the rate at which they were cleared.

Quantilation of stem cellfactor isoforms by competitive R T-PCR
As a result of differential splicing and postranslational events, human stem cell factor

can be found as a soluble or membrane-bound protein (Anderson et aI. , 1 990; Anderson et
aI . , 1 99 1 ; Flanagan et aI. , 1 9 9 1 ) . The biological activities of SCF/Kit interactions include
adhesion, migration (by way of chemotaxis or haptotaxis), survival, proliferation and
differentiation, and in some cases, activation (reviewed in Galli et aI . , 1 994), and significantly
different activities have been associated with each isoform (Toksoz et aI. , 1 992).

We

therefore felt that it was reasonable to hypothesize that altered regulation of SCF isoform
expression may have pathological consequences.
To evaluate the levels of expression of one isoform compared to the other, we set out
to develop a means to quantitate the relative amounts of each mRNA produced by a given
population of cells.

This laboratory had previously designed a competitive reverse

transcription polymerase chain reaction (RT-PCR) protocol with which to quantitate levels
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Figure 4. Effects of rmSCF'69 injections on severity of Nippos/rangy/lls brasiliensis infection:
adult worm counts. Daily injections and Nb infections were performed as in Figure I legend.
Mice sacrificed at day 16 post infection received continued daily injections of rmSCF'69 or
PBS (3 1 days total). 15 cm sections of small intestines were removed, and adult Nb worms
were counted. Data represent the mean ± SEM of worm counts in four mice. No worms
were seen in any of the mice at day 1 6.
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ofmRNA expression for the gamma chain of t h e murine high-affinity IgE receptor (Fc.RIy).
We used an adaptation of this technique in an attempt to determine the quantities of mRNAs
for both isoforms of stem cell factor.
As described in Materials and Methods, this protocol involves the use of a panel of
known quantities of a cRNA control fragment which is co-transcribed and co-amplified in the
RT-PCR reactions with cellular RNA, resulting in a competitive advantage for the species of
higher molar concentration. The products are distinguished from each other by agarose gel
electrophoresis, based on their size differences, and the relative quantities are determined by
comparing the densities of the resulting bands. The original amount of target mRNA can be
calculated based on the amount of cRNA control fragment needed to generate a similar
amount of product. We initially developed a protocol to evaluate mouse SCF expression.
B y using an antisense PCR primer which targets a sequence within exon 6, the quantity of
mRNA for the soluble isoform can be determined. In a separate set of reactions using an
antisense primer which anneals upstream of exon 6, the combined quantities of both isoforms
is obtained. The molar concentration of the membrane-bound isoform is calculated by
subtracting the value obtained for the soluble isoform of mRNA from that obtained for the
combined forms.
The results of a representative experiment are shown in Figure 5. The DNA fro m this
gel was subjected to Southern blot analysis and visualized by hybridization with a radiolabeled
oligonucleotide probe, followed by autoradiography (see Materials and Methods). In this
experiment, the amount of SCF mRNA in I Ilg of total cellular RNA (the amount added to
the original reaction mixture), is determined to be between 0.2 and 2 . 0 picograms, based on
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Figure 5 . Competitive RT-PCR for quantitation of mouse SCF mRNA. A constant amount
(I Ilg) oftotal RNA from BALB/c 3 T3 fibroblasts was added to decreasing amounts of m S CF
cRNA control fragment, as indicated. S amples were then reverse transcribed to cDNA and
amplified by polymerase chain reaction. Shown is an autoradiograph of the S outhern blot of
the amplified products.
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the relative intensities of t h e bands. Alternatively, t h e bands on an auto radiograph can be
assigned numerical values by densitometry, allowing for more accurate calculations.
We developed a similar protocol for the evaluation of human SCF.

However,

although the technique is highly sensitive and can be performed on very small quantities of
RNA, we concluded that it is overly labor intensive in requiring a dose response curve for

each experimental sample. Therefore we sought to detennine if our samples could be assayed
using a ribonuclease protection assay (RP A), which is ten times more sensitive that Northern
analysis, and could be used in side-by-side comparisons between samples.

Two isoforms of human stem cellfactor messenger RNA can be detected by a ribonuclease
protection assay

Schwann cells are a source of SCF (Ryan et aI . , 1 994) and mast cells, which express
Kit and respond to SCF, are hyperplastic in neurofibromas (Isaacson, 1 976). In light of the
above mentioned activities associated with the two isoforms of SCF (and their possible
contributions to pathological conditions), we set out to examine the expression of stem cell
factor isoforms in tissues from NF l and non-NF l patients.
In an effort to acquire a means by which the two isoforms of human stem cell factor
messenger RNA (SCF mRNA) could be discretely detected, a ribonuclease (RNase)
protection assay (RPA) was developed. RPA involves hybridization of a radiolabeled RNA
probe to a target mRNA by complementary base-pairing, and subsequent ribonuclease
digestion of all unhybridized RNA. This study utilizes a probe which is complementary to the
sequence encoding most of exons 5 and 6 of the SCF mRN A. A protected fragment 222
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nucleotides in length results from hybridization of the probe with an mRNA which includes
sequence encoded by exon 6 (the soluble isoform). When exon 6 is absent, as in the case of
the membrane-bound isoform, the protected fragment is 1 44 nucleotides long (see Figure 6).
To assess the ability of the RPA to detect the mRNA isoforms, the procedure was
performed on total RNA extracted from human fi b roblast-derived cell lines, because
fibroblasts are known to express SCF (Kitamura et aI., 1 989; Fujita et aI . , 1 989; Kitamura and
Fujita, 1 989; Jarboe and Huff, 1 989). Autoradiographic analysis of the gel reveals that bands
representing protected fragments of apparent lengths of 222 and 1 44 nucleotides result,
indicating that SCF mRNAs have been detected for the soluble and membrane-bound
isoforms, respectively (Figure 7).
In addition to the fi b roblast-derived cell lines, we performed the procedure on RNA
extracted from primary human fi b roblast cultures which had been derived by explantation of
surgical skin tissue. In 7 out of 7 samples tested, a band corresponding to a protected
fragment of 222 nucleotides was observed, suggesting expression of the soluble isoform of
SCF mRNA (Figure 8). As part of a collaborative effort led by Dr. Dome Yager (Division
of Surgery, Department of Medicine. Virginia Commonwealth University, Richmond,

Virginia), we included primary fibroblasts derived from keloid tissue in this study. Keloids
are characterized as progressively enlarging scars resulting from excessive collagen deposition
during connective tissue repair, and Dr. Yager' s work includes investigation of the
mechanisms by which keloids are formed. We sought to evaluate whether a change in S CF
i soform expression by the resident fi b roblasts played a part in this mechanism.

Our

preliminary conclusions are that there appears to be no change in SCF isoform expression by
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Figure 6. Ribonuclease protection assay for human S C F mRNA. Schematic representation
of the hybridization specificity of the probe used for RPA.
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Figure 7 . Autoradiograph of RPA on human fi b roblast-derived cell lines. RP A was
performed on 10 Ilg of total RNA as described in Materials and Methods. The human
fibroblast cell lines used are: (lane I) CCD I 8 ; (lane 2) Detroit 5 5 1; (lane 3) HS68; (lane 4)
KEL-FIB; (lane 5) MRC-9. Size markers (M) are shown to the left. Expected fragment sizes
of 222 and 1 44 nucleotides indicating the soluble and membrane-bound isoforms of S CF
mRNA, respectively, are indicated.
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Figure 8 . Autoradiograph of RP A on primary human skin fibroblasts. RP A was performed
on 1 0 Ilg of total RNA extracted from cultures of primary fibroblasts established by
explantation of human skin tissue. Data are representative of seven subjects tested. S amples
are: (lane I) 8N-normal skin; (lane 2) Edwards-keloid tissue; (lane 3 ) 1 6BN-normal skin from
an Afiican-Amencan donor; (lane 4) 3 0K-keloid tissue. S ize markers (M) are represented at
the left. Arrow indicates expected 222 nucleotide fragment size for the soluble isoform of
SCF rnRNA.
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keloid-derived fibroblasts, compared to those derived from normal skin.

Human malignant schwannoma cell lines express only the membrane-bound isoform of stem
cellfactor messenger RNA

The malignant schwannoma is a rare form of cancer which seems to have an increased
rate of incidence in NF l patients (Bernards et aI. , 1 992). We obtained cell lines derived from
four human malignant schwannomas and extracted RNA for analysis by RPA. In each of the
four human malignant schwannoma cell lines, a protected fragment of an apparent length of
1 44 nucleotides is seen (Figure 9, arrow), whereas no 222 nucleotide fragment is evident.
These data indicate that the cell lines exclusively express mRNA for the membrane-bound
isoform of SCF.

Other human malignant cell lines do not exhibit exclusive expression of the membrane
bound isoform ofstem cellfactor messenger RNA

The preferential expression of membrane-bound SCF mRNA by the malignant
schwannoma cell lines caused us to ponder whether this pattern of expression was in any way
related to the transformed phenotype of the cells. In order to determine if other human
malignancies also expressed the membrane-bound form, we obtained total RNA samples
extracted from human small cell lung carcinoma cell lines and a human breast cancer cell line,

and examined them for similar patterns of expression. Each of the samples tested appears to
express the soluble isoform of SCF mRNA (Figure 1 0) .
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Figure 9. Autoradiograph of RPA on human malignant schwannoma cell lines. RPA was
p erformed on 10 �g of total RNA extracted from malignant schwannoma cell lines as
described in Materials and Methods. Samples are: (lane I) NF- I T; (lane 2) S T8 8- 1 4; (lane
3 ) STS-26T; (lane 4) T265. Size markers (M) are shown. Arrow indicates the expected 1 44
nucleotide fragment size for the membrane-bound isoform of SCF mRNA.
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Figure 1 0 . Autoradiograph of RP A on human small cell lung carcinoma cell lines and a
human breast cancer-derived cell line. RPA was performed on 1 0 iJg of total RNA extracted
from human small cell lung carcinoma (SCLC) cell lines or a breast cancer line as described
in Materials and Methods. S amples are: (lane I) H I 46-SCLC; (lane 2) H209-SCLC; (lane
3) H249-SCLC; (lane 4) WBA-SCLC; (lane 5) MCF7-breast cancer line. S ize markers (M)
are shown. Arrow indicates the expected 222 nucleotide fragment size for the soluble isoform
of SCF mRNA.
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Expression of the exon 6-containing mRNA correlates with release of soluble SCF protein

Production of soluble stem cell factor involves at least two steps : a splicing event
which includes the exon 6-encoded sequence in the mRNA, and proteolytic cleavage of the
protein, which is initially expressed as a membrane-inserted protein (Anderson et aI . , 1 99 1 ) .
It is possible that SCF expression may be regulated, at least in part, at the proteolysis step (for
example, no cleavage of an exon 6-containing protein, resulting in membrane-bound S CF).
I n an effort to ascertain whether detection of exon 6-containing mRNA transcripts by
ribonuclease protection assay correlated with release of soluble stem cell factor by the same
population of cells, we performed a sensitive enzyme-linked immunosorbent assay (ELIS A)
on the culture supernatants of the cell lines used. SCF was detected in the supernatants of cell
lines which were found by RP A to express the soluble isoform of SCF mRNA (Figure 1 1 ) .
However, the culture supernatants o f the four malignant schwannoma cell lines, which
expressed only mRNA for the membrane-bound isoform as determined by RPA, contained
no detectable SCF (Figure I I ).

Neur()fibroma tissue and other Schwann cell-containing tumors express soluble SCF mRNA

Total RNA was extracted from surgically excised neurofibroma, and subjected to RP A
analysis. Figure 1 2 indicates that this tumor expresses the soluble (arrow), but not the
membrane-bound form of SCF mRNA. Other Schwann cell-containing tumors, including an
additional neurofibroma, a vestibular schwannoma, and an acoustic neuroma were evaluated
in a similar fashion. For comparison, a meningioma specimen was also included in this
experiment. No 1 44 nucleotide protected fragments were observed in any of the samples,
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Figure 1 1 . Enzyme-linked immunosorbent assay to detect soluble human SCF in cell culture
conditioned media. ELISAs were performed on conditioned media from the indicated cell
lines using a commercial kit. Results were obtained using an automated plate reader.
CCD I 8, HS68, and MRC-9 are human fibroblast cell lines. HT I 080 is a human fi b rosarcoma
cell line which was shown by RP A to express the soluble isoform of SCF mRNA (data not
shown). NF- I T, ST88- I 4, STS-26T, and T265 are human malignant schwannoma cell lines.
Sensitivity ofthe assay ranged from 3 1 .25 to 2000 pg/ml of human SCF. Data represent the
mean of duplicate wells. Similar results were obtained in three separate experiments.
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Figure 12. Autoradiograph ofRPA performed on neurofibroma tissue. 20 �g of total RNA
extracted from neurofibroma tissue was subjected to RPA as described in Materials and
Methods. Size markers (M) are shown. Arrow indicates the 222 nucleotide expected
fragment size for the soluble isoform of SCF mRNA. NF : neurofibroma.

80

M
300

200

1 00

NF

81
while the majority of the tumors revealed a fragment of222 nucleotides, indicating expression
of the soluble isoform of SCF mRNA (Figure 1 3 )

No SCF mRNA was detected in the

meningioma tissue.

Human malignant schwannoma cell lines exhibit low level expression of Kit

Normal rat and human Schwann cells have been shown to express stem cell factor, but
not its receptor, Kit (Ryan et aI . , 1 994). In that study, however, it was found that the ST881 4 human malignant schwannoma cell line simultaneously expressed both proteins, suggesting
that these cells may proliferate in response to autocrine stimulation (Ryan et aI . , 1 994).
Having obtained three additional human malignant schwannoma cell lines, we sought to
determine i f they also expressed Kit. In the course of pursuing a related project in this
laboratory, Christopher Shelburne analyzed the four cell lines by indirect immunofluorescence
and confocal laser cytometry. Figure 14 indicates that each of the four lines exhibits
fluorescence indicative of a low level expression of Kit (panels A-D). Corresponding samples
incubated with a non-specific mouse IgG, showed no fluorescence (not shown) . Further
analyses suggest that the Kit protein in each of these lines is truncated in some way, and bears
a novel point mutation which may cause the receptors to be constitutively activated
(manuscript in progress). HMC- I cells, which express Kit abundantly, are shown as a positive
control (panel E).

Kit is not detected on Schwann cells of neurofibroma or malignant schwannoma tumors

Neurofibromas are composed primarily of Schwann cells, but include a few other cell
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Figure 1 3 . Autoradiograph of RP A performed on human Schwann cell-containing tumors.

RPA was performed on 10 �g of total RNA extracted from human tumors as described in
Materials and Methods. Tumors include: (lane 1) neurofibroma; (lane 2) acoustic neuroma;
(lane 3 ) meningioma; (lane 4) vestibular schwannoma. S ize markers (M) are shown. Arrow
indicates the expected 222 nucleotide fragment for the soluble isoform of SCF mRNA.
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Figure 14. Photomicrographs of indirect immunofluorescence to detect Kit protein expression
by human malignant schwannoma cell lines. Cells were incubated with a monoclonal antibody
against human Kit. Bound antibodies were visualized using a fluorochrome-labeled secondary
antibody, followed by confocal laser cytometry. Samples are: (A) NF- l T; (B) ST88- 1 4 ; (C)
STS-26T; (D) T26 5 . The human mast cell line HMC- l (E) were used as a positive control.
The negative control was the KEL-FIB human fibroblast cell line (F) .
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types, including mast cells. We wished to detennine whether these Schwann cells express the
Kit receptor, offering a possible explanation for their hyperplasia. Sections of formalin-fixed
paraffin-embedded neurofibromas were evaluated for the expression of Kit protein by
immunohistochemistry as described in Materials and Methods.

Mast cells are known to

express Kit protein, and therefore serve as convenient internal controls for the staining
protocol. Indeed, Kit protein was easily detectable on mast cells (Figure 1 5, arrows). The
surrounding Schwann cells, however, show no evidence of immunoreactive protein. By using
differential interference contrast microscopy at a higher magnification (Figure 1 6) we were
better able to identifY the Schwann cells, based on their characteristic fibrillar morphology.
The detection of Kit protein on all four of the malignant schwannoma cell lines led to
our hypothesis that there may be a correlation between aberrant Kit expression by Schwann
cells and a transformed phenotype. However, the results of immunohistochemical analyses
of malignant schwannoma sections did not support this hypothesis. Once again, Kit expression
by mast cells was evident, but no Kit was detected on the Schwann cells of these tumors
(Figure 1 7) .

Growth of the HMC-I cell line is not supported by coclI/ture with o r conditioned media from
human malignant schwannoma cell lines

In light of the fact that both Schwann cells and mast cells are found in increased
numbers in neurofibromas (Isaacson, 1 976; Peltonen et aI . , 1 98 8 ; Johnson et aI . , 1 989), and
that S chwann cells make stem cell factor (Ryan et aI . , 1 994), we wanted to investigate the
possibility that either cell type may be inducing the proliferation of the other. We obtained
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Figure 1 5 . Photomicrographs o f immunohistochemistry t o detect Kit protein in neurofibroma
tissue sections. (A) Immunohistochemistry was performed on neurofibroma sections using
a polyclonal antibody agains human Kit as described in Materials and Methods. Arrows
indicate Kit+ mast cells. (B) Adjacent section stained with an isotype-matched control
antibody. Original magnification: 66X.
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Figure 16. High magnification photomicrographs of immunohistochemistry to detect Kit
protein in neurofibroma sections. Sections of neurofibroma depicted in Figure 1 5 viewed at
a higher magnification. (A) Kit+ mast cell. (B) Adjacent section stained with an isotype
matched control antibody. Original magnification: 3 3 0X.
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Figure 1 7 . Photomicrographs of immunohistochemistry to detect Kit protein i n malignant
schwannoma tissue sections. Immunohistochemistry was performed on thin sections of
human malignant schwannoma tumors as described in Materials and Methods. (A) Section
stained with a polyclonal antibody against human Kit. Arrows indicate Kit+ mast cells. (B)
Adjacent section stained with an isotype-matched control antibody. Original magnification:
1 3 ZX.
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the HMC- I cell line, which was derived from a patient with mast cell leukemia, and is thought
to represent a human mast cell line (Butterfield et aI. , 1 988), to grow in coculture with the
malignant human schwannoma cell lines.
Twelve separate experiments involving HMC- I cells in coculture with malignant
schwannoma cell lines, or HMC- I cells grown in the presence of conditioned media (CM)
derived from the schwannoma lines were performed. The proliferation of HMC- I cells,
determined either by 3H-thymidine uptake assays or by increases in cell number, was not upregulated in any of the experiments. Typical results are represented in Figure 1 8 . Oddly, in
early cultures of HMC- 1 cells in the conditioned medium of the ST88- 1 4 schwannoma line,
we noted a rapid demise of the HMC- I cells (data not shown). The cell death was not
occurring through an apoptotic pathway, according to the results of a terminal
deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay. Upon receipt of a
different clone of the ST88- 1 4 line from Dr. Jonathan Fletcher (Department of Pathology,
B righam and Women' s Hospital, Boston, MA), the experiments were repeated, and this
phenomenon was no longer observed (Figure 1 9), suggesting that the original clone likely
contained a toxic contaminant.

Characterization of murine bone marrow-derived mast cel/s clllillred with Schwann cel/
conditioned media from wild type or NFl-deficient mice

Efforts to conduct experiments examining potential paracrine effects of mast cells and
Schwann cells upon each other have been hampered by the difficulties involved in obtaining
and maintaining relatively pure populations of normal human mast cells and Schwann cells.
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Figure 1 8 . Proliferation of HMC- I cells cocultured with irradiated human fibroblast or
malignant schwannoma cell lines. Malignant schwannoma and KEL-FIB cells were irradiated
with 127Cs (4000 rads) and seeded onto a 96 well plate. HMC- l cells were co cultured with
the irradiated cells for 2 days. Each well was incubated for 4 hours after the addition of I IlCi
of 3H-thymidine, and the cells were harvested with a PHD cell harvester. Incorporation of 'H
thymidine was determined using a scintillation counter. Data represent the mean ± SEM of
triplicate wells.
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Figure 19. Daily cell counts ofHMC- l cells grown in 25% ST88- l 4 CM. HMC- l cells were
grown in a 25 cm2 flask in a 25% concentration of conditioned medium from cultured ST881 4 human malignant schwannoma cells. The number of viable HMC- l cells was determined
daily by trypan blue exclusion.
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The experiments described above were done with cell lines, which represent phenotypically
abnormal cells, and therefore do not serve as an adequate model system. Primary cultures of
mouse mast cells are routinely established in this laboratory, and attempts to isolate and grow
highly purified cultures of mouse Schwann cells have been successful in other labs, thereby
offering a potential source of cells with which to study interactions in the murine system. The
establishment of the NFl knockout mouse strains (Jacks et aI. , 1 994) allows for comparisons
between normal cells and neurofibromin-deficient cells .
W e obtained conditioned media from Schwann cell cultures derived from wild-type,

NFl

+1-, and

NFl

-1- mice from the laboratory of Dr. Nancy Ratner (Department of Cell

Biology, Neurobiology and Anatomy, College of Medicine, University of Cincinnati). We
cultured bone marrow-derived mast cells in 1 0% concentrations of the various Schwann cell
conditioned media and compared the cultures for differences in mast cell phenotype or rates
of proliferation. Alcian blue/safranin stains were done to determine the percentage of cells
containing safranin-positive (heparin-containing) granules, characteristic of the connective
tissue mast cell phenotype (CTMC). Our laboratory has previously used the shifting of alcian
blue/safranin staining to redder granulation as an indication of the presence of SCF in cell
conditioned medium (Ryan, 1 992). Cultures containing each of the conditioned media were
left untreated or were supplemented with either 50 ng/ml rmSCF, 50 U/ml rmIL-3 , or both.
Cytospin preparations of the cells were stained with alcian blue and safranin, followed by
microscopic examination. The total number of cells in five random 20X fields were counted,
and the percentages of cells with san-anin-positive granules were calculated (Table I ). Figure
20 depicts the appearance of cells grown in the absence of any conditioned media, and is
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Table 1 . Alcian blue/safranin staining of bone marrow-derived mast cells

Percent cel1s containing safra n i n-positive granules

n o added

50 ng/ml

50 Vlml

factors

rmSCF

rmIL-3

0%

86%

0%

Cells grown
in cDMEM
alone

SCF + IL-3

92%

Cel1s grown i n 1 0 % conditioned media su pplem ented with

50 U/ml rmIL-3

Cond itioned medium

Safranin-positive cells

cDMEM alone (no CM)

0%

BALB/c 3T3 fibroblast CM

1 7%

NFl +1+ Schwann cell eM

3 0%

NFl

+1-

Schwann cell CM

20%

NFl

-1-

Schwann cell CM

4%

1 00

Figure 20. Photomicrographs of alcian blue/safranin-stained bone marrow-derived mouse
mast cells grown with rmSCF, rmIL-3, or both. Bone marrow-derived mouse mast cells were
obtained as described in Materials and Methods. A1cian blue/safranin staining of cytospin
preparations was done after 5 days of culture with (A) 50 ng/ml rmSCF, (B) 50 Vlml rmIL-3,
or (C ) SCF + IL-3 .

101

1 02
consistent with the results of previous studies in this laboratory.
Cells grown in the presence of various conditioned media are represented in Figure
2 I. An increase in the percentage of safranin-positive cells in CM-containing cultures given
only IL-3 (Table 1 ), when compared to the absence of safranin staining in cultures which
contain no conditioned media, suggests that the conditioned media contains one or more
factors which contribute to the phenotypic shift. The results obtained with cultures containing
BALB/c 3 T3 fibroblast conditioned medium are similar to those from previous work in this
laboratory (Jarboe et aI. , 1 989) which led to the discovery of stem cell factor.
Changes in the rate of proliferation of the mast cells were assessed based on
incorporation of 3H-thymidine during DNA synthesis. After three days of culture in the
different combinations of conditioned media and additives noted above, 1 !lCi oeH-thymidine
was added to each well. After an additional 24 hours in culture, the amount of incorporation
was determined using a scintillation counter (Figure 22).
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Figure 2 1 . Photomicrographs of alcian blue/safranin-stained bone marrow-derived mouse
mast cells grown in Schwann cell-conditioned media from wild-type or NFl knockout mice.
Alcian bluelsafranin stains were done on cytospin preparations of bone marrow-derived
mouse mast cells grown for 5 days with 50 U/ml rmIL-3 in the presence of various cell
culture-conditioned media. Shown are representative examples of cells grown in 1 0%
BALB/c 3 T3 fibroblast conditioned medium (A), or Schwann cell-conditioned medium fro m
wild type (B), NFl +1- (C), or NFl -1- mice (D).
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Figure 22. Proliferation of bone marrow-derived mouse mast cells grown in Schwann cell
conditioned media from wild-type or NFl knockout mice. Bone marrow-derived mast cells
were cultured for 3 days with cytokines and 1 0% concentrations of the conditioned media
indicated. 1 IlCi oflH-thymidine was added to each well, and the plate was incubated for an
additional 24 hours. Cells were harvested, and 3H-thymidine incorporation was determined
using a scintillation counter. Data represent the mean ± SEM of triplicate wells.
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Discussion

The research described in this dissertation deals with some of the patterns of
expression and biologic activities of stem cell factor. SCF is capable of acting on any cell
which expresses its receptor, Kit. The Kit+ cells addressed in this dissertation research were
mast cells and malignant schwannoma cell lines. Both Schwann cells and mast cells are found
in high numbers in the neurofibroma nodules associated with NFl , and Schwann cells have
been shown to make SCF.

The hyperplastic Schwann cells in these lesions have an

abnormally high tendency to become malignant. Many such solid tumors have been shown
t o involve an SCFIKit autocrine loop. Thus, neurofibromas and malignant schwannomas
appear likely to have a complex dependency on the SCFlKit complex, whether in an autocrine
or paracrine signalling pattern. This dissertation research investigates various aspects of S CF
and Kit expression, with particular emphasis on which isoform of SCF might be expressed.
To date, very few studies have attempted to make a distinction between different forms of
S CF expression, membrane or soluble, and relate them to biologic or pathologic situations.
Membrane-bound and soluble SCF clearly have different biologic activities.
Membrane-bound SCF is more effective to induce proliferation and differentiation (Miyazawa
et aI. , 1 995), whereas soluble SCF is more likely to be involved in chemotaxis of Kit+ cells
(Blume-Jensen et al., 1 9 9 1 ) and augmentation of mediator release from mast cells (Columbo
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et aI. , 1 992; Wershil et aI . , 1 992).

Based on the previous work of John Ryan in this

laboratory, we suspected that S chwann cell-derived S CF might play a role in the mast cell
hyperplasia associated with NFl neurofibromas. However, it was not clear whether the S CF
might be more likely to recruit mast cells, or cause mast cells to proliferate in situ, or both.
Furthermore, we did not know what SCF isoform might be made by the Schwann cells.
Before investigating soluble or membrane SCF effects on cells we suspected of
expressing Kit only weakly, we first tested the effect of high concentrations of soluble S CF
(recombinant) on strongly Kit+ cells, peritoneal mast cells. SCF and Kit have been implicated
i n biologically relevant interactions involving adhesion, migration, survival, proliferation,
differentiation, and activation (reviewed in Galli et aI. , 1 994). We suspected that changes in
expression of SCF and/or Kit resulting from a mutation of the NFl gene leads to the
hyperproliferation of S chwann cells in a neurofibroma, perhaps partly due to recruitment of
mast cells. Therefore, we first wanted to demonstrate, in a more straight forward model
system, stem cell factor-induced recruitment or proliferation of mast cells in vivo, so we
injected high doses ofrmSCF1 69 into the peritoneal cavities of mice, and later examined them
for site-specific mast cell hyperplasias. In addition, we compared the responses of otherwise
healthy mice to those which had been infected with the intestinal helminth Nippostrongylus
brasiliensis (Nb).

It is known that Nb infection results in a muco sal mastocytosis

(Befus and

Bienenstock, 1 984), and has been used by this and other labs as a model system to study mast
cell development. We expected that administration of rmSCFI69 would result in increased
numbers of peritoneal mast cells, and further thought that the greater numbers of mast cells
in the infected mice would lead to a more rapid clearance of the adult worms in the gut,
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thereby suggesting that SCF might be acting as a therapeutic agent.
Surprisingly, SCF treatment resulted in decreases in the number of mast cells found
in the peritoneal cavities of mice treated with rmSCF1 69 , compared to control mice inj ected
with phosphate-buffered saline (PB S) alone (Figure 1 ) . The drop in peritoneal mast cell
number in response to SCF treatment is similar to that previously observed with Nb infection
(Huff et aI., 1 995). Kasugai and colleagues have also noted a loss of mast cell precursors in
the blood of mice infected with Nb (Kasugai et aI. , 1 995). Our results are, however, in
contrast to previous studies in which subcutaneous inj ections of recombinant SCF in mice led
to the appearance of large numbers of mast cells at the dermal site of injection (Zsebo et aI. ,
1 990b; Tsai e t aI. , 1 99 1 ) . There was n o significant difference in the numbers o f mast cells i n
b a c k dermis preparations o f control o r SCF-treated mice (Figure 2), indicating that
intraperitoneal injections of rmSCF1 69 do not seem to confer systemic effects. In addition, no
significant differences in the degree ofNb infection were noted between PB S-treated controls
and S CF-treated mice, in terms of the number of adult worms in the gut (Figure 4), or the
daily expul sion of eggs in the feces (Figure 3 ) .
To explain why the intraperitoneal administration o f high doses of rmSCF169 d o e s not
lead to proliferation of mast cells, but rather reduction, we suggest that the mast cells could
be activated and induced to degranulate, thereby rendering them undetectable by our methods.
S CF has been shown to induce mediator release from purified human skin mast cells
(Columbo et aI . , 1 992) and from purified mouse peritoneal mast cells (Coleman et aI. , 1 993)
in vitro. This hypothesis is supported by our observations that SCF treatment combined with
7 d ay Nb infection, which contributes both IgE plus antigen, resulted in lower numbers of
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peritoneal mast cells than with either treatment alone, suggesting augmented degranulation.
Alternatively, the lower numbers of mast cells detected in SCF-treated mice may reflect a
change in the pattern of mast cell homing, as suggested by Kasugai and colleagues to be the
mechanism of loss of mast cell progenitors from blood during Nb infection (Kasugai et aI ,
1 995). Further studies would be needed in this model system to test these hypotheses. We
conclude from these experiments that the effects of high concentrations of soluble SCF are
less predictable than previously thought.
The major part of the dissertation research dealt with the possible etiologic role of the
S CFlKit complex in NF l lesions. Although the manifestations of type I neurofi b romatosis
rarely lead to fatal consequences, NF l causes significant morbidity. In addition to the medical
symptoms of the pain and mechanical limitations resulting from the size and location of
neurofibromas, the patient must also deal with the unfortunate social stigma associated with
being deformed. Developmental dysfunctions and learning disabilities occur more frequently
in children and adolescents with NF 1 than in the general population (Dilts, 1 997), creating a
tendency toward (or perhaps resulting from) a sense of low self esteem. Perhaps due to the
low incidence of mortality associated with NF l , the degree of public awareness has not
correlated well with the relatively high rate of occurrence of the disease. Although this may
create obstacles in the way of gaining support for research efforts, it is not an indication of
the relative importance of such research. The cloning of the NFl gene (Cawthon et ai , 1 990;
Viskochil et ai , 1 990; Wallace et aI . , 1 990) and the subsequent characterization of the gene
product, neurofibromin, has greatly improved our understanding of the disease, and may
possibly lead to the development of practical clinical interventions. However, even the NFl
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gene cloning studies do not provide an adequate explanation for the overproliferation of
S chwann cells and mast cells in the lesions. The purpose of this study has been to obtain
information about some of the very basic mechanisms at work in NF I, specifically those
involving stem cell factor and Kit interactions.
We chose to focus on SCF and Kit due to a logical association of certain facts : that
mast cells (which express Kit and respond to S CF) are present in the nervous system
associated with normal nerves (Bienenstock et aI. , 1 99 1 ); that mast cells are increased at sites
of nerve damage and repair (Isaacson, 1 976; Olsson, 1 97 1 ) or in nerve-associated tumors,
such as neurofibromas and schwannomas (Isaacson, 1 976); and that S chwann cells produce
stem cell factor (Ryan et a!. , 1 994). We further sought to determine whether aberrations in
the expression of either SCF (i.e. changes in isoform) or Kit (ectopic expression by S chwann
cells) may be involved in the development of the tumors characteristic of NFl .
Human stem cell factor exists as either a soluble or membrane-bound protein, resulting
from alternative splicing and specific proteolysis (Anderson et a! . , 1 99 1 ). Each isoform is
associated with distinctly significant biological activities (see discussion in Literature Review),
which led us to the notion that a failure in SCF regulation resulting in aberrant expression of
either form may contribute to pathology. Since we wanted to evaluate the relative expression
ofthe two forms of SCF rnRNA, we developed techniques with which we could discriminate
and quantitate them. Although a competitive RT-PCR protocol was effective at quantitating
mRNA levels (Figure 5), we found that a ribonuclease protection assay (RPA) was better
suited for sample-to-sample comparisons. Therefore, RP A was used throughout this study
to detect SCF mRNA isoforms.
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In early experiments using RNA extracted from human fibroblast-derived cell lines,
we determined that we were able to detect either isoform of SCF mRNA by this method
(Figure 7). However, in addition to the bands representing the protected fragments of 1 44
nucleotides (membrane) and 222 nucleotides (soluble), we also noted additional bands
indicating protected fragments of approximately 1 05, 1 75 , and 3 00 nucleotides. Since the
radiolabeled transcript used as a probe in this protocol is approximately 300 nucleotides long,
the band of that size likely represents excess probe which remained unhybridized and
undigested. By reducing the concentration of ribonucleases, and lowering the temperature
of the digestion reaction, the 1 05 nucleotide fragment was eliminated, leaving the expected
fragments, appearing as doublets, and the unexpected doublet around 1 75 nucleotides.
Doublets such as these may result from transient strand separation at AU-rich regions of the
RNA, allowing for RNase cleavage at that site, or they may represent non-specific cleavage
due to secondary RNA structure.

Similar unexpected fragments have been reported

elsewhere (Huang et a! . , 1 992; Kauma et a!. , 1 996).
Having developed an RNase protection assay capable of detecting both SCF isoforms,
we examined SCF isoform expression from malignant schwannoma cell lines and fro m
neurofibroma tissues. T h e malignant schwannoma is a rare cancer o f S chwann cell origin
affecting much less than 1% of the general population (Cutler and Gross, 1 93 6) . This rate
of incidence is increased to up to 2% in NF I patients (Ponder, 1 990; Nimura, 1 992), which
supports the notion that neurofibromin may function as a tumor suppressor (Weinberg, 1 99 1 ) .
Because o fthe infrequency o f occurrence of malignant schwannomas, cells and tissue samples
from such tumors are in short supply, and are very difficult to obtain for research purposes.
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We have, however, obtained four cell lines which have been derived from human malignant
schwannomas, and have used them throughout this study in place of actual tumors or primary
cultures of schwannoma-derived cells. We note here that cell lines are not completely
accurate representations of the phenotypic characteristics of their in vivo cell counterparts,
and interpretations of the data must be made with that in mind. We examined the stem cell
factor mRNA expression of the malignant schwannoma cell lines by RP A. In every case, only
the membrane-bound isoform was detected (Figure 9). These fi n dings were in contrast to
results obtained with RNA from primary cultures of normal and keloid-derived human
fibroblasts (Figure 8). The same pattern was observed in multiple subsequent experiments
u sing the same or different RNA extractions. In view of the fact that, of the five human
fibroblast cell lines used in the early RP A experiments (Figure 7), the two lines which
expressed mRNA for the membrane-bound isoform of S CF grew much more rapidly than the
other three which expressed the soluble isoform mRNA (Table 2), we wondered if the
expression of primarily membrane-bound SCF correlated with the transformed phenotype of
these cell lines. Therefore, we sought to determine if other S CF-expressing malignant cells
exhibited a similar pattern of isoform expression.
A panel of small cell lung carcinoma (SCLC) cell lines have been characterized with
respect to stem cell factor expression (Krystal et aI . , 1 996). We obtained RNA extracted
from these, as well as from a breast cancer cell line, to address the question of a potential link
between membrane-bound SCF expression and malignancy. The detection of only the soluble
isoform of SCF mRNA in each of these samples (Figure 1 0) leads us to the conclusion that
expression of the membrane-bound form is not required for a malignant phenotype in stem
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Table 2. Patterns of stem cell factor and Kit expression and growth rates of cultured cells

Cell lines

SCF isoform

Kit expression

Rate of growth

CCD I 8

soluble

ND*

slow

Detroit 5 5 1

membrane

ND

rapid

HS68

soluble

ND

slow

HT l O80

soluble

ND

slow

KEL-FIB

membrane

negative

rapid

MRC-9

soluble

ND

slow

Primary fibroblasts

soluble

negative

ND

NF- I T

membrane

positive

rapid

ST88- 1 4

membrane

positive

rapid

S TS-26T

membrane

positive

rapid

T265

membrane

positive

rapid

*ND

=

not determined
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cell factor-expressing cells. However, these data do not rule out the possibility that any
correlation between preferential expression of the membrane-bound isoform and malignancy
(or perhaps simply hyperplasia) may be dependent upon the cell type. In other words, it may
be true for Schwann cells, but not small cell lung carcinoma or breast cancer cells .
The fact that these malignant schwannoma lines exclusively express th e membrane
isoform of SCF is striking in itself. A search of the literature does not reveal any other
primary cell preparation or cell lines which exhibit such tight regulation toward the membrane
S CF isoform. Thus, these malignant schwannoma lines may prove to be a good model system
for studying how the alternative splicing of exon 6 of SCF is regulated. Majumdar and
colleagues have studied SCF isoform regulation, but only in SCF transfectants, not in
naturally occurring circumstances (Majumdar et aI. , 1 996).
To explore the possibility that all Schwann cell hyperplasias, not just S chwann cell
malignancy, might be characterized by expression of the membrane-bound isoform of stem
cell factor, we extracted RNA from tissues obtained by surgical excision of neurofibroma,
vestibular schwannoma, acoustic neuroma, and meningioma tumors.

Except for

meningiomas, these all contain increased numbers of Schwann cells, but the S chwann cells are
not transformed. Meningiomas were included as an example of a neural-associated tumor not
involving Schwann cells. Ribonuclease protection assays performed on these samples indicate
that the soluble isoform of stem cell factor, but not the membrane-bound form, is being
expressed in these tissues (Figures 1 2 and 1 3) . As expected, the meningioma showed little
SCF expressio n of either isoform. It should not be assumed that the source of the SCF
mRNA being detected in the other tumors is exclusively Schwann cells, because the tumors
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contain other SCF-producing cell types, including fibroblasts. The methods used here do not
allow for the determination of the source of the mRNA from a mixed population of cells.
Nevertheless, Schwann cells do represent a major cellular constituent of each of these lesions,
and if there had been exclusive expression of membrane SCF, it would likely have been
revealed by the RNase protection assay.
In an earlier study in this laboratory, it was reported that the ST88- 1 4 human
malignant schwannoma cell line expressed Kit, while normal human and neonatal rat S chwann
cells did not (Ryan et al . , 1 994). These findings, along with the detection of stem cell factor
production by the same cells, were suggestive that the ST88- 1 4 cells might be responding to
an autocrine growth loop. Coexpression of S CF and Kit has been reported in a variety of
malignancies (Hibi et al., 1 99 1 ; Toyota et al., 1 993 ; Inoue et al., 1 994; Hines et a! . , 1 995), and
transfection studies have provided strong evidence of a correlation between coexpression and
growth factor independence in small cell lung carcinoma lines (Krystal et a! . , 1 996). With the
acquisition of three additional human malignant schwannoma cell lines, through related studies
performed by Christopher Shelburne in this laboratory, we sought to determine if these also
expressed Kit. Indirect immunofluorescence staining, using a monoclonal antibody directed
against human Kit, was performed on the three cell lines, as well as the ST88- 1 4 line. The
preparations were analyzed using a confocal laser cytometer, which revealed expression of
Kit protein at low levels on all four malignant schwannoma lines (Figure 1 4) . Additional
characterizations, including immunoprecipitation of Kit protein from the cell lines, suggest
that the protein may be truncated.

Moreover, RT-PCR amplifi c ation and subsequent

sequencing of fragments of the c-kit mRNA indicate a novel point mutation in the kinase
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region of Kit which may lead to constitutive receptor activation (Shelburne et a!. , manuscript
i n preparation).

Taken together, these findings offer two possible explanations for the

transformed phenotype of the malignant schwannoma cell lines: the cells are constantly
induced to proliferate due to simultaneous expression of SCF and Kit, or they bear a mutation
in Kit which causes it to be constitutively activated, leading to unregulated growth.
As mentioned above, although the use of cell lines as a model system offers the
advantages of abundance and availability, their phenotype may diverge from that of the
corresponding cells in vivo.

To further characterize the S chwann cells of malignant

schwannomas as well as those of neurofibromas in situ, we obtained formalin-fi x ed, paraffin
embedded sections of each tumor type and examined them for Kit expression. No primary
cell cultures were available from these sources to perform experiments similar to those
performed on the malignant schwannoma lines. As we have reported in the Results section,
by performing immunohistochemical analyses of the sections, using a polyclonal antibody
specific for Kit protein, we were able to detect abundant Kit expression by the resident mast
cells (Figures 1 5 - 1 7) . However, no Kit protein was detected on the Schwann cells by this
method. We can not rule out the possibility that Kit may be expressed at levels too low to be
detected by this method. Indeed, mature mast cells such as these are likely to express much
higher numbers of Kit molecules than other cells (reviewed in Galli et aI . , 1 994). We are
currently developing techniques whereby we can adapt the immunohistochemistry protocol
such that it can be analyzed with the highly sensitive confocal laser cytometer, thereby
offering the same degree of sensitivity as was used with the malignant schwannoma cell lines.
Production of substances with potential mitogenic effects has been observed in mast
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cells (Pennington et aI. , 1 9 9 1 ) and S chwann cells (Ridley et aI. , 1 989; Ohi et aI . , 1 990). In
addition, Schwann cells derived from a neurofibroma of an NF I patient appear to secrete
growth factor activity which is not observed in S chwann cells from genetically normal
individuals (Sheela et aI. , 1 990). We have hypothesized that NFl Schwann cells produce
factors (SCF and perhaps others) which are chemoattractive and mitogenic for mast cells.
Thus, the mast cells might be drawn to the site where they, in turn, secrete growth factors to
which the Schwann cells are responsive, resulting in the formation of a neurofibroma. Others
have suggested similar theories concerning the involvement of mast cells in neurofibroma
growth. Riccardi has suggested that mast cells may accumulate following local trauma, or in
response to tropic factors, and that their secretions may induce abnormal proliferation in other
cells due to the NFl mutation, resulting in neurofibroma growth (Riccardi, 1 990).
To test whether human S chwann cells might up regulate the growth of human mast
cells (such as might occur in NF I neurofibromas), we used malignant schwannoma lines and
the HMC- I mast-like line, using both co-culture experiments and conditioned medium
experiments. No upregulation ofHMC- 1 growth or differentiation was observed. The slight
decreases in HMC- I growth were likely due to slight nutritional deprivation due to dilution
with spent (conditioned) medium. Also, since HMC- I cells have an activating Kit mutation
(Furitsu et al. , 1 993), any upregulation due to SCF might be hard to detect. In addition, the
malignant schwannoma lines might not well represent Schwann cells from NFl neurofibromas.
It would likely be informative to establish cocultures of human mast cells and S chwann

cells derived from both genetically normal individuals and NF I patients, and monitor them for
changes in phenotype. These changes might relate to maturation, differentiation, proliferation,
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or activation. We are not aware of any studies of this sort to date, which is possibly an
indication of the difficulties inherent in the derivation of pure cultures of human mast cells and
Schwann cells. In an effort to circumvent these obstacles and approximate the conditions as
closely as possible, we have performed preliminary experiments in the mouse system u sing
conditioned media from NFl knockout S chwann cells kindly provided by Dr. Nancy Ratner
at the University of Cincinnati. We have cultured bone marrow-derived murine mast cells
(BMMC) in the presence of mouse Schwann cell conditioned media (SCCM). Ihe sources
of the SCCM include Schwann cells derived from wild-type, and NFl heterozygous (+/-) and
homozygous (-/-) knockout mice. Changes in the phenotype or growth rate of the BMMC
were then measured by alcian blue/safranin staining and tritiated thymidine incorporation,
respectively.
Alcian blue!sa/Tanin staining of mast cells has been used to differentiate between cells
of the mucosal (MMC) or connective tissue (CIMC) phenotype. Ihe granules of CIMC
contain heparin, which binds the safranin dye, resulting in pink or red staining. Stem cell
factor is produced by cells in the connective tissue microenvironment in vivo, and drives mast
cell progenitors toward the CIMC phenotype, whereas the MMC result from the influence
ofIL-3 in the mucosal microenvironment. In in vitro studies, a shift toward red granulation
in alcian blue!safranin stained mast cell cultures is an indication of the presence of SCF i n the

culture medium. A similar approach was used successfully by John Ryan in his dissertation
research i n this lab to detect biologically active SCF in other mast cell co-cultures. In our
experiments with Schwann cell-conditioned media (Figure 2 1 ), we noted that, in the presence
ofIL-3 alone, SCCM from both NFl +/+ (wild type) and NFl +/- mice shifted the cultured
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mast cells toward the CTMC phenotype as did cultures containing fibroblast-conditioned
medium (FCM). In addition, we observed that the wild type SCCM induced a greater shift
than did the +/-. However, NFl / SCCM appeared to have a diminished capacity to exert
- -

this effect. It is possible that the Schwann cells of the homozygous knockout mice do not
release soluble SCF into the medium (perhaps due to a change in isoform expression), and
therefore do not drive the mast cells as effectively toward the CTMC phenotype. This
possibility is particularly intriguing in view of the observation that the malignant schwannoma
lines do not make soluble SCF (Figure I I ). The complete loss of neurofibromin in these cells
may lead to the secretion of other cytokines which, in concert with exogenous SCF and IL-3,
may co-stimulate the proliferation of the cultured mast cells. Indeed, DNA synthesis was
increased in mast cells grown in NFl -/- SCCM in the presence of both S CF and IL-3
compared to all other culture conditions. A possible explanation for why NFl -/- S chwann
cell-conditioned meduim augments growth but does not change phenotype is that whereas
other cytokines in S chwann cell conditioned medium could likely augment mast cell growth
(Figure 22), the ability to cause a change toward the connective tissue phenotype is a biologic
activity that has been much more closely linked to SCF specifically.
A possible explanation for the intermediate ability of NFl +/- S chwann cell
conditioned medium to cause a shift in alcian blue/safranin staining is that a mutatio n on a
� NFl allele may cause a pru:ti.a! decrease in the production of soluble SCF by S chwann
cells. If so, these cells might actually be models for Schwann cells in NFl , a genetic disease
which is caused by an autosomal dominant mutation (heterozygous). On the other hand,
when both alleles are non-productive, as is certainly the case for both the mouse NFl
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knockout S chwann cells and the ST88- 1 4 malignant schwannoma (Reynolds et aI . , 1 992),
soluble SCF bioactivity, as indicated by safranin-positive granules is barely detectable (Table
1). Studies involving the ST88- 1 4 malignant schwannoma line show that, although a single
copy of the NFl gene appears to remain intact in these cells, NFl rnRNA expression was
found by Northern analysis to be substantially reduced or absent (Reynolds et aI. , 1 992).
Moreover, it has also been reported that ST88- 1 4 cells express extremely low levels of
neurofibromin protein (DeClue et aI . , 1 992). It has been suggested that the greatly reduced

NFl expression in this tumor cell may be due to a somatic mutation acquired by the intact
allele, resulting in either greatly reduced transcription or message instability (Reynolds et aI. ,
1 992). I t is also possible that a homozygous mutation may lead t o the transformation o f the
cell, as has been suggested for the ST88- 14 human malignant schwannoma (Reynolds et aI . ,
1 992).

Additional studies are required t o determine i f lack o f soluble stem cell factor

expression by S chwann cells might be caused by severe neurofibromin deficiency.
The observation that only the membrane-bound form of SCF rnRNA is expressed by
the four schwannoma cell lines implies that there may be a correlation between S CF isoform
expression and control of Schwann cell proliferation. It is interesting that faster rates of
proliferation were observed in cultures of fibroblast cell lines which expressed the membrane
bound isoform, compared to soluble SCF-producing cells (Table 2). Although no malignant
schwan noma solid tumors were available for analysis by RP A, neurofibroma, vestibular
schwannoma, and acoustic neuroma tumors, each of which is characteristically slow-growing
and non-invasive, all expressed the soluble SCF isoform (Figures 1 2 and 1 3 , Table 3 ) . In the
future, it is hoped that, through collaborations with other laboratories, the experimental design
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Table 3 . Patterns of SCF and Kit expression by solid tumors

Tum o r

S C F isoform

Kit expression

neurofibroma

soluble

negative

malignant schwannoma

ND*

negative

vestibular schwannoma

soluble

ND

meningioma

none detected

ND

acoustic neuroma

soluble

ND

*ND

=

not determmed
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can be expanded to include cultures of S chwann cells in mast cell-conditioned media, as well
as cocultures of the two cell types from normal and knockout mice.
In summary, the findings reported here indicate a significant involvement of stem cell
factor and Kit in at least some of the pathological manifestations of NF l , perhaps in part
through faulty regulation of SCF i soform expression. We first determined that high doses of
recombinant stem cell factor may cause degranulation or rerouting of peritoneal mast cells,
because their numbers are decreased in mice after repeated daily intraperitoneal injections of
rmSCF169

In conjunction with Christopher Shelburne, we have found that four human

malignant schwannoma cell lines all aberrantly express the Kit receptor, and that this protein
may be truncated and constitutively activated. We further suggest that loss of neurofibromin
function may have a direct effect on stem cell factor biologic activity, by regulating the
induction toward a membrane isoform switch. There are two lines of evidence which suggest
a possible role for neurofibromin in SCF isoform expression : the mouse NFl knockout data
and the human ST88- 1 4 malignant schwannoma data, both of which lack neurofibromin
activity and appear to express the membrane isoform of SCF. In fibroblasts, there appears
to be a correlation of membrane SCF with more rapid rate of growth. A better understanding
of the mechanisms by which expression of the stem cell factor isoforms is regulated is
necessary to defi n e a possible relationship between SCF expression and neurofibromin
function. The malignant schwannoma cell lines and the NFl knockout mice likely represent
good model systems in which these mechanisms can be studied. This information could lead
to the development of therapeutic strategies for the treatment of the symptoms of NF I .
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